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S U M M A R Y
E X E C U T I V E  S U M M A R Y
The malaria component o f the Africa Child Survival Initiative-Combatting Child­
hood Communicable Diseases (ACSI-CCCD) Project (1981-1993) added greatly to 
the understanding o f the impact o f malaria on the health and survival o f African 
children and clarified and promoted the strategies necessary to control malaria in 
sub-Saharan Africa. The malaria effort documented ways in which the malaria para­
site contributes to morbidity and mortality o f young children: acute malaria illness, 
chronic or persistent parasitemia with anemia, and perinatal malaria infection in the 
mother, which can cause low birth weight and early infant mortality. The project’s 
malaria activities helped determine the efficacy of control measures and assisted 
programs with training, health education, and monitoring and évaluation-support 
strategies necessary to limit the impact o f malaria in African countries south of the 
Sahara.
At the outset o f the project, knowledge o f the epidemiology and control o f malaria 
in Africa was incomplete, the small number o f existing malaria programs were largely 
ineffective, and few international donor organizations supported malaria programs in 
this region. International attention has now been drawn to the seriousness o f the 
malaria problem, and a network o f donors has been established. Most important, 
however, is that the capacity o f African nations to control the disease that is respon­
sible for the deaths o f more than 1.5 million children in Africa each year has been 
strengthened through renewed leadership, refined policies, and improved systems for 
program implementation.
Each of the 12 ACSI-CCCD countries with endemic malaria developed malaria- 
related activities. Although countries participated in these activities to varying de­
grees, most nations were involved in efforts in these areas: leadership and policy 
development, operational research (including studies designed to improve imple­
mentation of malaria programs and to m onitor the spread of resistance to 
antimalarial drugs), and support strategy development.
Information from the project’s malaria activities has been shared widely in meetings, 
and many scientific articles on various aspects o f malaria epidemiology and control 
(based on the work done in the project) have been published. The ACSI-CCCD 
experiences have greatly influenced the approach to malaria control in many other 
African countries and in the World Health Organization, particularly in the African 
regional headquarters.
The accomplishments o f the malaria component o f ACSI-CCCD provide a firm 
scientific basis for the challenge ahead in the 1990s: to implement malaria control 
programs that will improve child survival in Africa.
I N T R O D U C T I O N
I N T R O D U C T I O N  T O  T H E  R E P O R T
This report is written for the United States Agency for International Development 
(A.I.D.) and for others who have responsibility for planning, implementing, evalu­
ating, and managing international public health programs. The report summarizes 
what we at the Centers for Disease Control and Prevention (CDC) have learned 
from our 12-year involvement in the malaria component o f the Africa Child Sur­
vival Initiative-Combatting Childhood Communicable Diseases (ACSI-CCCD) 
Project. Our work and that o f our many partners have provided the foundation for 
developing effective malaria control strategies and for successfully implementing 
them in sub-Saharan Africa in the 1990s.
Part One provides a history of malaria within the project, reviews the major 
malaria-related accomplishments, examines the lessons learned, and outlines priori­
ties for malaria control for the next decade.
Part Two summarizes important malaria-related activities in the individual 
African countries that participated in ACSI-CCCD.
The Lists o f  Publications contain articles written about malaria projects 
funded by A.I.D. as well as articles about work linked to ACSI-CCCD activities but 
not directly funded by A.I.D.
In addition, the ACSI-CCCD work on malaria in sub-Saharan Africa is the basis of 
two other documents. Addressing the Challenges o f Malaria Control in Africa  
provides detailed recommendations for controlling malaria through case manage­
ment and prevention and for implementing malaria control programs. Malaria 
prevention in pregnancy: the effects o f treatment and chemoprophylaxis on placental 
malaria infection, low birth weight, and fetal, infant, and child survival presents the 
results o f a major study conducted in Mangochi, Malawi, from 1987-1990. These 
three documents are available from:
ACSI-CCCD Technical Coordinator 
International Health Program Office 
Centers for Disease Control and Prevention 





H I S T O R Y
S e c t i o n  1 
B r i e f  H i s t o r y
The ACSI-CCCD1 Project, an A.I.D. health initiative, evolved in response to 
requests from sub-Saharan African countries for increased technical support to 
improve child survival. CCCD began in 1981 as an 8-year project, and A.I.D. 
extended activities until September 1993. Over the course o f the project, all 12 
CCCD countries with endemic malaria were involved in malaria activities; the length 
of national involvement varied from country to country (Figs. 1-1 and 1-2).














Figure 1-2. C C C D  P artic ipating  C ountries
t---- 1---- 1---- 1---- 1 i i i i i i i r~
81 82 83 84 85 86 87 88 89 90 91 92 93
Years
*No endemic malaria in Lesotho.
1_The original name o f  the project was CCCD; ACSI was added in 1988. ACSI-CCCD will be abbreviated as 
CCCD throughout this document.
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The original program design of CCCD in 1981 focused on targeting interventions in 
two areas: vaccine-preventable diseases and diarrheal diseases. Discussions with 
Ministry o f Health (M O H ) officials in Africa revealed their strong interest in includ­
ing malaria as part o f the child survival agenda, and malaria was included as a focus of 
operational research. However, when early data collected by countries identified 
malaria as the major cause o f child mortality, control measures were defined and con­
sensus reached on appropriate control strategies. Malaria then became a third major 
component o f the CCCD project. While intervention activities focused on prompt 
treatment o f malaria in children, operational research remained a central element of 
malaria activities in the CCCD Project.
When CCCD began field operations in 1982, malaria control in sub-Saharan Africa 
was hampered by lack o f knowledge o f effective treatment and prevention strategies, 
inadequate national malaria control programs, and the reluctance o f international 
donors to be involved in malaria control in this region. Although some important 
studies had evaluated vector control and drug use approaches in pilot areas in Africa, 
more work was needed to evaluate the efficacy of the treatment and prevention mea­
sures recommended by the World Health Organization (W HO). Plasmodium falci­
parum, the malaria parasite responsible for nearly all the malaria-related illness and 
death in sub-Saharan Africa, had begun to lose its sensitivity to chloroquine (CQ), 
the most commonly used antimalarial drug. This resistance was first detected in East 
Africa in 1978. However, the extent o f chloroquine-resistant Plasmodium falciparum 
(CRPF) in sub-Saharan Africa was not known. In many countries, clinicians and pub­
lic health staff had no clear guidance on malaria control strategies; only 4 o f the 12 
malaria-endemic CCCD countries had malaria control units. The international 
donor community did not support malaria control in Africa because the disease was 
believed to be an intractable problem and because the global eradication efforts of 
previous decades had not succeeded.2
The CCCD malaria component moved malaria control efforts forward by assisting in 
development o f the national leadership and the infrastructure necessary to develop 
and implement malaria control strategies, by defining more precisely the epidemiol­
ogy of malaria, and by testing the effectiveness o f recommended and alternative con­
trol measures. By expanding the knowledge o f the impact o f malaria and the 
potential effectiveness o f control efforts, CCCD has thus focused international atten­
tion on malaria and has made possible a renewed attack on this disease that kills in 
excess o f 1.5 million children under 5 years o f age each year in sub-Saharan Africa.
2 The W H O  Global Malaria Eradication Programme was conducted in the 1950s and 1960s. Despite marked im ­
provement in malaria control in some countries, the program did no t achieve its objective and was considered a 
failure in many places. Program efforts in Africa (except Ethiopia) were limited to  a few pilot projects.
ACCOM PLISHM ENTS
S e c t i o n  II
A C C O M P L I S H M E N T S  O F  T H E  M A L A R I A  C O M P O N E N T  O F  C C C D
The accomplishments o f the malaria component o f CCCD can be seen in four areas: 
strengthened leadership and policies o f national malaria programs, expanded recog­
nition o f the impact o f malaria infection and disease on children, increased technical 
understanding o f malaria control measures, and improved support components 
required for control (surveillance and health information systems, training and super­
vision, health education, and logistics).
Leadership and Policy Development
Strengthened national programs through leadership development. At the beginning of 
the project in 1981, only 4 o f the 12 malaria-endemic CCCD countries (Guinea, 
Nigeria, Swaziland, and Togo) had national malaria program managers. Each had 
been trained primarily in vector control, a vestige o f the strategy promoted interna­
tionally during the eradication efforts o f the 1950s and 1960s. One o f the first tasks 
o f the malaria component o f the CCCD project in each malaria-endemic country was 
to encourage the identification of a national malaria coordinator and to assist in the 
development o f a national malaria unit to develop and implement a control policy 
based not on vector control, but on appropriate case management, i.e., treating 
malaria/febrile illness with antimalarial drugs. By 1987, the M O H  o f each malaria- 
endemic CCCD country had appointed a coordinator o f the malaria program and 
had formed malaria units. Three countries (Malawi, Nigeria, and Zaire) also formed 
national malaria advisory committees.
The achievements o f CCCD in malaria control would not have been possible without 
the competence and extraordinary commitment o f these malaria coordinators, pro­
gram managers, and M O H  officials who supported them. Through their active par­
ticipation and leadership in malaria activities, they strengthened the capacity o f their 
countries to control malaria and aided the development o f malaria control capabilities 
o f neighboring countries. Through their contributions to malaria control efforts, 
many have become known regionally and internationally as experts. At the end of 
the CCCD project, perhaps the most im portant asset o f national malaria programs is 
their experienced and committed leadership.
Strengthened malaria control policy statements in CCCD countries. In nine participat­
ing countries (the Central African Republic [CAR], the Republic o f the Congo, Cote 
d'Ivoire, Guinea, Malawi, Nigeria, Rwanda, Togo, and Zaire), national workshops 
and training sessions were held between 1984 and 1989. In these sessions, national 
treatment strategies were examined, antimalarial drug efficacy was assessed, revisions 
in treatment strategy were made, and national plans were proposed and developed.
In 1991 and 1992, the "Malaria Initiative "developed by CDC, in conjunction with 
W H O , sponsored training workshops that addressed policy development (1991) and 
planning and programming (1992) for malaria control in Africa. Using a structured 
interactive approach that emphasized current issues, shared experiences, and deci­
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sion-making by participants, the workshops enabled country representatives to draft 
nationally tailored malaria control policies and plans. These workshops promoted 
collaboration among the African malaria program managers and were instrumental in 
improving malaria policies, plans, and programs in 21 French-speaking countries in 
Africa, including all eight francophone participants in CCCD (Burundi, CAR, the 
Republic o f the Congo, Cote d'Ivoire, Guinea, Rwanda, Togo, and Zaire).
Impact o f  Malaria Infection and Disease
The research conducted as part o f the malaria component o f CCCD was instrumen­
tal in expanding the knowledge o f the health impact o f malaria infection and disease 
in Africa. First, early reviews o f data collected from routine health information sys­
tems examined the morbidity and mortality due to malaria, focusing on the effect on 
various age groups and on the severity o f illness. In Malawi, Swaziland, Togo, and 
Zaire, special investigations were undertaken, mainly at health facilities. Surveillance 
for drug resistance was established to measure the efficacy o f treatment with antima- 
larial drugs. In several countries, operational research studies documented the 
increase in CRPF and a concurrent increase in malaria-associated morbidity and mor­
tality. Additionally, a large 3-year project designed to examine the effect o f malaria in 
pregnant women and the benefits o f antimalarial treatment and chemoprophylaxis, 
the Mangochi Malaria Research Project (MMRP), was conducted in Malawi. This 
research provided a tremendous amount o f new knowledge about malaria and its 
impact on African children.
Malaria infection and disease can affect children in three ways (Fig. 1-3): as an acute 
disease (febrile illness), as a chronic condition (malaria-associated anemia), and as a 
perinatal condition (placental malaria infection in a pregnant woman leading to low 
birth weight [LBW] in the newborn). Each o f these conditions increases a child's 
risk o f dying, either as a direct result o f malaria disease or one of its complications, 
anemia or LBW.






3 A baby born weighing less than 2500 grams is considered to  be low birth weight.
A C C O M P L I S H M E N T S
• Acute febrile illness, w ithout symptoms or signs o f other illnesses, is the opera­
tional definition o f malaria in a malarious area. If untreated or ineffectively 
treated, this illness may progress to a severe disease with delirium, seizures, and 
coma leading rapidly to death.
• Repeated and chronic malaria infections, caused by frequent exposure to 
malaria infection or to ineffectively or incompletely treated malaria episodes, lead 
to progressive destruction of red blood cells, eventually recognized as anemia. As 
the consequences o f chronic parasitemia intensify, the child becomes more sus­
ceptible to other illnesses, such as pneumonia, which might not be fatal in a 
nonanemic, healthy child. The child is also at risk o f death from severe anemia.
• Perinatal malaria infection, caused by malaria infection in the mother during 
pregnancy, causes LBW, which is a major determinant o f infant mortality.
CCCD helped refine the understanding of each of the three categories o f malaria 
infection and disease. As a result o f new information about the effect o f the disease, 
the focus o f malaria control shifted from the traditional emphasis on treating acute 
febrile illness to controlling chronic malaria infection, which is more important for 
reducing mortality than was previously thought. Whereas a fatal outcome of an acute 
attack is relatively unusual, occurring in less than 1 in 1000 malaria cases, the major­
ity o f malaria mortality is due to a process o f repeated and chronic parasitemia that is 
ineffectively or incompletely treated (Slutsker et al. 1993a). Consequently, the chal­
lenge is not only to manage febrile illness but to recognize which children are at risk 
o f severe disease from recurrent or chronic parasitemia so that their disease can be 
treated early and appropriately. In the area o f perinatal infection, CCCD studies have 
defined the clinical and epidemiologic impact o f malaria during pregnancy. In addi­
tion, drug efficacy studies have led to the formulation of more simplified and effec­
tive strategies for decreasing the effect o f parasitemia during pregnancy, even in areas 
o f CQ  resistance.
Acute febrile illness
Calculated the incidence o f acute febrile illness in children. Community surveys were 
conducted that provided estimates o f the frequency o f acute febrile illness, which, in 
the absence of microscopic confirmation of parasites in the blood, is considered to be 
malaria. Surveys conducted in five sub-Saharan African countries between 1983 and 
1986 showed that between 14% (Guinea) and 34% (Togo) o f the children had had a 
febrile illness in the previous 2 weeks, which translates into rates o f 3-9 m alaria/ 
febrile illness episodes per child per year (Breman and Campbell 1988).
ACCOMPLISHMENTS
Calculated and estimated the incidence o f malaria-associated death in children. Because 
in this region many children die at home and not at a health facility (Steketee et al. 
1993a), the exact number o f childhood deaths caused by malaria is difficult to deter­
mine. CCCD studies used various approaches to determine the number o f deaths 
that were caused by malaria or a malaria-associated illness.
One study followed infants in Malawi for 2 years after birth. Malaria and malaria- 
associated anemia accounted for 18.7% o f infant deaths (malaria-specific infant mor­
tality rate = 30 /1000). For children surviving their first year, malaria and malaria- 
associated anemia accounted for 25.6% of deaths (malaria-specific second year mor­
tality rate = 34 /1000). Most o f the infant (65%) and second-year (62%) deaths 
occurred at home (Steketee et al. 1993a).
At Mama Yemo Hospital in Zaire, pediatric and mortuary records for 1 year were 
examined to determine the effect o f malaria on hospitalized children (Greenberg et 
al. 1989a). Children under 14 years o f age who were diagnosed with malaria on the 
basis o f clinical and parasitologic data had a 21.1% inpatient case-fatality rate (CFR).4
Another study attempted to establish reasonable estimates o f CFRs using the Delphi 
survey technique (Sudre, Breman, and Koplan 1990). In a Delphi survey, respon­
dents are repeatedly asked the same questions; each time they are questioned, they 
are given other respondents' answers and asked to respond again to obtain a consen­
sus. Nineteen medical experts, all with extensive experience treating malaria in Afri­
can children, were surveyed to learn what they judged to be likely CFRs for acutely 
febrile children contracting malaria in areas o f differing resistance.5 Estimated CFRs 
for acute malaria illness ranged from .045% in areas o f low and moderate resistance to 
5% in areas o f high resistance.
When these studies are examined in the context o f supporting information from 
other sites (The Gambia, Kenya, Nigeria), several aspects o f malaria stand out. Acute 
severe disease among hospitalized children has a high CFR, in the range o f 20%. But 
most o f the malaria-associated deaths are not seen in facilities, and the summary rates 
o f malaria-associated death (approximately 30 deaths/1000 infants or children), 
when applied to African populations in moderately to highly endemic areas, lead to 
an estimate o f more than 1.5 million malaria-associated deaths annually in Africa.
Assessed the value o f the operational case definition and refined it to reflect the increased 
knowledge o f the impact o f malaria infection and illness. To prevent a life-threatening 
illness caused by malaria infection, health workers need a case definition for malaria 
illness that will identify children who need prompt treatment with an antimalarial 
drug. Traditionally, "malaria" has been the diagnosis for a patient who comes to a 
clinic with a recent history of fever or presence o f elevated temperature and no other
4The case-fatality rate is the ratio o f  the number o f  deaths to the num ber o f cases.
5 D rug resistance occurs when malaria parasites are no longer eliminated by the drug acting in synergy with the 
individual's established immune protection against the parasite. The three levels o f drug resistance (RI = low,
RII = moderate, RIII = high) are based on parasitologic response. RI resistance is characterized by temporary dis­
appearance o f  the parasite from peripheral blood followed by return >7 days after therapy. RIII resistance is char­
acterized by limited (<75% o f initial density) or no reduction in parasite density in peripheral blood (World Health 
Organization 1973). Resistance varies by geographic area and by age (acquired immunity may reduce the resis­
tance level in older individuals).
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obvious explanation for the fever (pneumonia, measles, otitis media, etc). However, 
such a clinical definition presents several problems. First, CCCD studies in Malawi 
and Zaire and other studies in Burkina Faso (Baudon et al. 1988) and in Niger (Oli- 
var et al. 1991) have shown that history o f fever can be a poor predictor o f malaria 
parasitemia; consequently, much over treatment occurs, and children with fever 
caused by another illness may not be properly treated. Another more serious problem 
is that fever does not characterize malaria-associated anemia, which is caused by 
repeated or chronic malaria parasitemia.
CCCD studies were conducted to determine ways to make the clinical definition 
identify more accurately those patients with malaria illness (a more "specific" defini­
tion). For example, children admitted to a hospital emergency ward in Kinshasa, 
Zaire, with an axillary temperature o f at least 37.5°C (comparable to an oral temper­
ature o f 38°C or a rectal temperature o f 38.5°C) were more likely to be parasitemic 
than children with lower temperatures (Hedberg et al. 1989). In Malawi, para­
sitemia was associated with an axillary temperature >37.3°C, history o f fever within 
the preceding 48 hours, reduced appetite, and reduced fluid intake (Pappaioanou et 
al. 1991). A few studies defined parasite density cutoffs (> 2000 /m m 3; > 5 0 0 0 / 
mm3; or > 10 ,000 /m m 3 of blood) above which malaria infection was more likely to 
be the cause o f the fever (Trape, Peelman, and Morault-Peelman 1985) and corre­
lated directly the levels o f parasitemia and increased temperature (Delfini 1968). 
Others examined the predictive value o f fever and found that fever is a better predic­
tor o f parasitemia during high transmission season than during low malaria transmis­
sion season (Olivar et al. 1991; Rougemont et al. 1991). These studies 
demonstrated that the addition of specific signs and symptoms can increase the spec­
ificity o f the diagnosis for malaria.
Greater specificity, however, can result in reduced sensitivity. In other words, a case 
definition encompassing these additional signs and symptoms would identify a lower 
proportion of patients with malaria illness. The challenge therefore is to make the 
case definition more specific without compromising its sensitivity. By ascertaining or 
excluding other causes o f fever, both microscopy (to determine parasite presence and 
level) and other laboratory tests (chest radiograph, blood culture, lumbar puncture) 
could improve the specificity o f the definition without changing its sensitivity. H ow ­
ever, laboratory facilities are usually limited and expensive; hence, microscopy and 
other examinations are rarely available in health facilities in Africa, especially in rural 
areas.
Anemia is an important consequence o f malaria and a major contributor to malaria- 
associated mortality. Since children may become anemic because o f malaria w ithout 
being febrile, criteria are needed to identify children with malaria-associated anemia. 
A broader case definition to establish which children need antimalarial treatment 
therefore requires both an assessment of fever and a systematic evaluation for anemia. 
Although laboratory determination of hematologic status would identify anemic chil­
dren, few peripheral health facilities in Africa can routinely perform hemoglobin or 
hematocrit evaluations. Clinical signs, e.g., palmar crease, nailbed, or tongue pallor, 
can be used to recognize anemic children. Epidemiologic criteria, such as defined 
age groups o f children most likely to become anemic, can be useful in identifying
9
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anemic children in need of treatment. One CCCD study in Malawi showed that in 
an area o f high malaria transmission, malaria-associated anemia was common, but 
limited mostly to children between 6 and 24 months o f age; in this area, all children 
in this age group presenting with fever should receive treatment with a highly effec­
tive antimalarial to clear parasitemia and prevent malaria-associated anemia.
The overriding goal o f malaria case management is to treat children promptly with an 
effective antimalarial if they are at risk o f developing a life-threatening illness due to 
malaria infection. Therefore, clinicians and public health specialists need a sensitive 
case definition, even though its use will cause some aparasitemic children to receive 
an antimalarial drug. Consequently, although CCCD studies have provided ways to 
refine the clinical case definition o f malaria, "fever or a history o f fever within the previ­
ous 48 hours without symptoms o f another illness" should continue to be used in a set­
ting o f endemic malaria transmission in Africa. Where trained workers can provide 
microscopic diagnosis, the case definition may be expanded to include "fever or his­
tory o f fever within the previous 48 hours and parasitemia o f any density." Although fur­
ther work is required to determine necessary treatment for anemic and severely 
anemic children, serious consideration should be given to treating these children 
with antimalarial drugs.
Assessed the economic burden o f malaria to the people and the nation o f Malawi. In 
addition to the suffering from illness and death that malaria causes, this disease exacts 
a heavy economic toll on both the families and the nations o f sub-Saharan Africa. A 
study conducted in Malawi found that the average family spends 5% o f its income on 
treating and preventing malaria illness (Ettling and McFarland 1993). Very low 
income households (those earning less than $150 per year) spend a much greater 
proportion o f their income, 23.3%, on malaria treatment and prevention measures.
In addition, indirect costs to households, measured in lost productivity caused by 
adult illness or by the time adults spend caring for sick children, are 3.5% of house­
hold income. In sum, total annual costs o f malaria, both direct and indirect, range 
from 8.5% o f the annual average income for all households to 26.8% o f the income 
for very poor households.
At the level o f the health system, the cost o f malaria is also high. Direct costs are esti­
mated at $1.03 million for outpatient treatment in health facilities and $1.08 million 
for inpatient treatment. These costs represent 10.1% of the annual expenditures o f 
the M OH. Estimates o f costs attributable to premature malaria mortality and mor­
bidity range from $31.7 million to $83.9 million. With a gross domestic product o f 
$1.7 billion in 1991, such losses represent a substantial economic burden to Malawi 
(Ettling and McFarland 1993).
Although few studies o f the economic impact o f malaria have been conducted, the 
situation in Malawi is likely representative o f other malaria-endemic countries in sub- 
Saharan Africa. Beyond the burden of morbidity and mortality o f malaria lies its 
enormous impact on individual and household productivity and national develop­
ment.
Chronic malaria infection and the development o f  anemia
Documented the role o f severe anemia associated with malaria and its impact on infant 
mortality. We now clearly understand that malaria-associated mortality is due not 
only to acute malaria infection that progresses to severe disease but increasingly to 
anemia associated with malaria. With the spread o f CRPF, areas in central Africa 
have reported an alarming number o f children brought to clinics with both malaria 
and severe anemia associated with malaria (Lackritz et al. 1992; Hedberg et al. 
1993). Studies o f hospitalized children in East Africa identified severe anemia, often 
associated with malaria, as a leading cause o f morbidity and mortality: one-third o f 
pediatric admissions and one-half o f the children who died in hospitals had hemoglo­
bins below 5.0 g /d L  (Lackritz et al. 1992). Furthermore, blood transfusions to 
treat severe anemia carry the additional risk o f human immunodeficiency virus (HIV) 
infection (Greenberg et al. 1988). More judicious use o f blood transfusions is there­
fore warranted (Lackritz et al. 1992).
Documented the importance o f hematologic recovery6 in treating malaria and tested effi­
cacy o f alternative antimalarial drugs to achieve recovery. Studies o f malaria and ane­
mia in children in Kenya (a non-CCCD country) and Malawi (CCCD-supported) 
have demonstrated the importance of using a drug that will rapidly clear parasitemia 
to allow hematologic recovery (Bloland et al. 1993). O f the children with both 
malaria and anemia (<8 g /d L ) in settings where CQ  had not been effective in clear­
ing parasitemia, those who received sulfadoxine-pyrimethamine (SP) improved sig­
nificantly more than those who received CQ  (Fig. 1-4). Thus, treatment o f 
parasitemic children with an effective antimalarial drug that clears the parasitemia is 
critically important to allow these children to return to normal hematologic status.
6 Hematologic recovery is defined as the return to  the preillness level o f  hemoglobin concentration.
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Perinatal infection: malaria in pregnancy and its effect on birth weight and 
infant mortality
Determined which pregnancies were at greatest risk for the adverse effects o f malaria 
infection. CCCD studies in Burkina Faso, Malawi, and Zaire confirmed that pregnant 
women in their first or second pregnancies had higher frequencies o f parasitemia, 
higher parasite densities, and higher rates o f LBW babies than those in later pregnan­
cies (Steketee et al. 1988a; Cot et al. 1992; Steketee et al. 1993a). The studies high­
lighted the importance of focusing malaria prevention efforts on these pregnant
Found that symptoms o f malaria do not always accompany the presence o f parasites in the 
bloodstream or in the placenta o f pregnant women. In Malawi, results o f a study o f the 
effectiveness o f chemoprophylaxis among pregnant women revealed that none o f the 
pregnant women who were parasitémie at enrollment in the study and just over 1 in 
10 who developed parasitemia while taking CQ  prophylaxis had either fever or other 
signs and symptoms o f malaria. Thus, a prevention strategy based on treating only 
symptomatic pregnant women, as suggested by some health officials, would not pre­
vent the majority o f malaria infections in pregnant women (Steketee et al. 1988a).
MALARIA D ISE A SE
women.
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Quantified the relationship between placental malaria infection and LBW in an area of 
moderate to high transmission. The Mangochi Malaria Research Project found that 
16.6% of all infants (and 28.0% of infants born to primigrávidas) born in this area had 
LBW (Steketee et al. 1993a). Approximately 10% of LBW could be attributed to pla­
cental malaria parasitemia. A number o f maternal characteristics were also found to 
be associated with LBW, but once a woman becomes pregnant, malaria is one of the 
few risk factors for which intervention is possible. The infant mortality rate for LBW 
babies (257 /1000) was roughly twice that o f babies o f normal weight (128 /1000). 
Although other risk factors were associated with neonatal and infant mortality, LBW 
was found to be a major determinant o f this mortality.
Demonstrated that an effective antimalarial drug can be used in pregnant women to 
reduce the frequency o f LBW. The MMRP demonstrated that mefloquine (M Q), used 
as initial treatment followed by weekly prophylaxis, reduced the frequency of break­
through infections (development o f parasitemia while taking a drug, following clear­
ance of parasitemia), placental malaria, and LBW and that the greatest reduction in 
the number o f LBW babies could be achieved for babies born to women in their first 
or second pregnancies (Steketee et al. 1993a).
Relationships between malaria and other diseases
As knowledge of the full impact o f malaria infection and disease improved, so did 
awareness o f the connections between fever and parasitemia, and between fever and 
other potentially life-threatening diseases or conditions, such as pneumonia, bactere­
mia, diarrheal disease, hypoglycemia, and HIV.
.7Determined that in children current clinical case definitions for malaria and pneumonia 
do not differentiate between the tw’o diseases. Pneumonia is one of the major causes of 
morbidity and mortality in African children, especially in infants. A study conducted 
in Malawi showed that children with clinical evidence o f pneumonia almost always 
have fever, the chief sign and symptom of a malaria infection (Redd et al. 1992). It is 
not clear, however, whether malaria increases a child's risk o f pneumonia or whether 
the diseases simply share a common clinical presentation.
Identified a drug effective in treating both malaria and pneumonia. In a CCCD study in 
Malawi, the efficacy o f cotrimoxazole, one of the three first-line drugs for the treat­
ment o f pneumonia, was evaluated for its success in treating falciparum parasitemia in 
children less than 5 years o f age (Bloland et al. 1991). Despite a regimen that could 
easily result in poor compliance-two doses daily for 5 days-cotrimoxazole was found 
to be an effective treatment for children who have both malaria and pneumonia.
Observed a clinical overlap in disease manifestations. A study o f diarrheal disease 
among children in Côte d'Ivoire found that many children with diarrhea had both 
bacteremia and malaria infections. Although children with bacteremia or malaria may
7 The case definition for malaria when microscopy is unavailable is the presence or history' o f  fever w ithout other 
obvious cause (W HO 1986). The case definition for pneumonia is presence or history o f  cough, accompanied by 
an increase in respiratory rate.
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show symptoms of febrile illness, each disease requires a different treatment and must 
be diagnosed properly. In this 1991 study, bacteremia could be distinguished from 
malaria only by laboratory examination, which is not available in most health facilities 
(Lee et al. 1992).
Examined the role o f multiple infections in sick children. The previously mentioned 
study of children from Cote d'Ivoire also found that severely ill children were more 
likely to have signs o f dehydration, bacteremia, parasitemia, severe anemia, and mal­
nutrition than those less severely ill (Lee et al. 1992).
In a 1988 study o f hospitalized children in Zaire, common causes o f fever were 
malaria parasitemia and bacteremia, which were not possible to differentiate without 
the use o f microscopy and blood culture (Hedberg et al. 1989). Bacteremia was 
present in 16% o f severely ill children, and although it was an im portant cause of 
fever, bacteremia was not commonly associated with parasitemia.
Found that hypoglycemia was associated with both malaria illness and death and with 
therapy using quinine. Work with Gambian children (White et al. 1987) indicated 
that hypoglycemia is a manifestation o f severe malaria and is caused by glucose con­
sumption by the parasite. In addition, in this study, children with severe malaria and 
hypoglycemia were more likely to die than those with only severe malaria. Hypogly­
cemia was also associated with therapy using quinine, the recommended drug for 
severe malaria. W hether or not hypoglycemia contributes to death or whether it sim­
ply reflects a severe, often fatal, infection is not clear. Regardless, treatment o f para­
sitemia with quinine and the assessment and treatment o f hypoglycemia with glucose 
in severely ill children is warranted.
Identified HIV as a risk factor fo r  malaria in pregnancy. Recent work in Malawi showed 
that HIV-positive pregnant women were more likely than HIV-negative women to 
have a higher prevalence and density o f placental malaria infection, which in turn is 
associated with LBW (Steketee et al. 1993b).
Malaria Control Measures
One of the im portant contributions o f the malaria component o f CCCD was the 
evaluation o f the effectiveness8 o f control measures. These studies addressed two 
important issues:
• Determining drug regimen and drug efficacy9among children and pregnant 
women
• M onitoring the progression o f CRPF and providing data needed to revise 
national malaria policies through the establishment o f national drug-testing sur­
veillance systems
8 Effectiveness can be defined as the improvement in health outcom e that a treatm ent or prevention strategy can 
produce in typical community-based settings.
9 Efficacy can be defined as the improvement in health outcome that a treatm ent or prevention strategy can pro­
duce in expert hands under ideal circumstances.
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Developed a standardized protocol for assessing the efficacy o f anti malarial drugs. The 
protocol developed was first used in individual operational research projects and then 
became a national surveillance method in several countries. The essential feature of 
this protocol was the modification of the 7-day in vivo test developed by W HO for 
use in evaluating malaria parasite response to antimalarial drugs (Table 1-1). In the 
W HO scheme, infected persons were followed daily for 7 days after therapy and 
weekly thereafter for 3 weeks (Bruce-Chwatt 1986). The modified version devel­
oped by the CCCD project examined a younger group of children (less than 5 years 
o f age) to reflect the actual at-risk population in most o f sub-Saharan Africa and 
required a follow-up only on days 2, possibly 3, and 7. Temperatures o f children 
were assessed to determine clinical response to therapy. The follow-up was later 
extended to 14 days to detect recrudescences (Ekanem et al. 1990) and to 28 days to 
monitor hemoglobin concentrations (Bloland et al. 1993).
An additional modification to the W HO in vivo test included a reduction in the sam­
ple size. A sampling scheme dictated by sequential analysis (Lemeshow and Stroh 
1988) was used to allow for quick decisions and for fewer participants in drug effi­
cacy studies. This was done by calculating the effect on total efficacy rate o f the suc­
cess or failure o f the drug in each group o f individuals and then determining if more 
children needed to be included in the testing. This sampling system was used to 
ascertain whether the drug success rate was at least 99% or the failure rate was at least 
10%, the cutoffs considered adequate for formulating national policy (Khoromana et 
al. 1986; Breman et al. 1987)
Table 1-1. CCCD Modification of WHO In Vivo Test
Ages o f participants 
Parasite levels
Use o f drugs
Blood smears
Health status o f patients
W H O  7-day in vivo test
6-14 years (usually)
>800 asexual form s/m m 3 
(usually)
No history o f antimalarial drugs 
for 1 week. Negative Dill-Glazko 
urine test for 4-aminoquinolines 
Thick and thin blood smears daily 
from Day 0 to  Day 7, weekly to 
Day 28
Asymptomatic school children
Follow-ups Day 1 through Day 7, weekly to
Day 28
Num ber o f patients and analysis "At least 30 persons" but no defi­
nite scheme
CC C D -m odified test
<5 years
>1000 or 2000 asexual fo rm s/?mm
Negative Dill-Glazko, Haskins, or 
Saker-Solomons test for 4-amino- 
quinolines*
Thick and thin blood smears Day 
0, Day 2, Day 7, Day 1 4 J,
Day 2 8 f
Preferentially symptomatic. Ex­
cluded if too  ill to be treated oral­
ly. Axillary temperature taken 
each visit.
Day 2, Day 31, Day 7, Day 14J, 
Day 28 J
Dictated by statistical sampling 
using a modification o f sequential 
analysis§
*See revision of field urine tests in text.
t Day 3 follow-up for those still parasitemic on Day 2.
*Days 14 and 28 for assessment of hemoglobin added in later studies.
^Sample size was established to detect greater than 10% resistance or less than 1% resistance with 90% confidence. An initial group of 
31 children was tested; the sample size was increased if the estimated prevalence of resistance fell between 1% and 10%.
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Developed field tests to evaluate antimalarial drug use in children and pregnant women. 
Improved field methods to detect CQ  and SP in urine (and blood) were developed 
and field tested. These test methods, which were frequently used to examine home 
use o f antimalarials or patient compliance with chemoprophylaxis, have now become 
the standard (Steketee et al. 1988b; M ount et al. 1989).
Drug efficacy studies: acute illness
Refined the goal o f drug use in antimalarial therapy. Traditionally, the goal o f malaria 
therapy had been to eliminate parasitemia entirely. However, in a 1984 CCCD- 
sponsored study in Malawi, investigators believed that in areas where malaria reinfec­
tion was likely to recur soon after treatment, clearing parasitemia to resolve an acute 
febrile episode was not necessary (Khoromana et al. 1986). Thus, in the early years 
o f CCCD, the goal o f treatment for uncomplicated malaria was to provide resolution 
of the symptoms of malaria (Breman and Campbell 1988). Although infection is nec­
essary for an individual to develop immunity to malaria disease, persistent parasitemia 
may cause anemia, which can be life threatening. Information provided by later 
studies in Malawi and Kenya o f children with malaria parasitemia and very low hemo­
globin concentrations (<8 g /d L ) demonstrated the need for parasite clearance for at 
least 1 month to allow clinical and hematologic recovery, particularly in children less 
than 3 years o f age, who were identified to be at greatest risk for anemia and anemia- 
associated mortality (Bloland et al. 1993). A single treatment dose of SP provided 
the necessary parasite clearance in these studies. Consequently, understanding the 
goal o f drug use became clearer, and parasite clearance for at least 1 month was 
found to ensure resolution o f febrile illness and hematologic recovery in young chil­
dren.
Assisted malaria-endemic countries with developing national policy for dosing regimens 
in response to increased knowledge o f antimalarial drug efficacy. In Malawi, when 25 
m g /k g  o f CQ  base over a 3-day period was more effective than a single dose of 10 
m g /k g  (Khoromana et al. 1986), this dosage became the CCCD recommendation, 
as well as Malawi's national malaria treatment policy. Although Togo found that a 
single dose o f 10 m g/kg  of CQ  base was effective in 1984, the government decided 
to adopt a 25 m g /k g  policy in 1989 as CRPF spread across Africa. Côte d'Ivoire 
also adopted the same policy of 25 m g /k g  in 1986, even after finding that a single 
dose o f 10 m g /k g  o f CQ  base was effective (Soro et al. 1989).
A 1985 study in several regions o f Zaire evaluated both a single dose of 10 m g /kg  
and a dosage of 25 m g /k g  given over 3 days. Because o f the greater decrease in par­
asitemia and fever with 25 m g /kg , even among children with resistant parasites, 
Zaire's M O H  adopted 25 m g /k g  as first-line treatment for their national malaria 
control plan (Paluku et al. 1988).
The standard treatment in 1986 in Rwanda o f 50 m g /k g  of CQ  base over 6 days, 
representing the dosage prevalent in Burundi and Zaire in the 1970s and 1980s, was 
shown to be no more effective than 25 m g /k g  over 3 days (Sexton et al. 1988). This 
information led Rwanda’s M OH to recommend the lower dosage.
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Found evidence, on the basis o f results o f parasitologic and clinical responses, to support 
a change from CQ as a first-line drug. Chloroquine was retained as the first-line drug 
in areas where it remained effective in reducing parasite densities and producing clin­
ical improvement, even if parasitemia was not completely cleared. However, studies 
in 1990-1991 showed that alternative drugs should be considered if 7-day in vivo 
tests revealed clinical failure10 and hematologic failure11 greater than 10% (Bloland 
et al. 1993). The drugs that now meet the criteria o f both effectiveness and afford­
ability in areas o f high resistance to P. falciparum in sub-Saharan Africa are combina­
tions o f a sulfa drug and a dihydrofolate reductase inhibitor (e.g., sulfadoxine- or 
sulfalene-pyrimethamine) (Bloland et al. 1993). CCCD studies led Malawi to change 
to SP as its first-line drug in 1992.
Showed that a more costly antimalarial may actually be more cost-effective. A recent 
study of the cost-effectiveness o f antimalarial treatment used a model based on sur­
vey and surveillance data, dosages based on W HO recommendations, and direct cost 
o f the drug to the health-care system (Sudre et al. 1992). These factors were found 
to have the most influence on the cost-effectiveness o f an antimalarial drug: cost, 
compliance rates, and efficacy or the level o f parasite resistance to the drug, with the 
prevalence of high-level drug resistance having the greatest effect. This analysis con­
cluded that in settings o f no resistance, CQ  had the best cost-effectiveness ratio in 
cost per case cured and cost per death prevented. However, to prevent death in areas 
of high CQ  resistance (between 14% and 31% of R III), SP, which is more expensive 
per dose than either CQ  or amodiaquine, proved to be the most cost-effective o f the 
three.
Documented the need in Africa to change from CQ as a first-line choice for complicated 
illness (severe malaria). The increasing resistance to CQ  also affected drug choice for 
cases o f severe or complicated malaria, which manifests in children as cerebral malaria 
or severe anemia. Studies in Southeast Asia, where CQ  resistance had been docu­
mented in the 1980s, demonstrated the efficacy of quinine in cases o f severe illness 
(Chongsuphajaisiddhi et al. 1981; Suebsaeng, Wernsdorfer, and Rooney et al. 1986). 
A CCCD study in Zaire in 1987, which used intravenous quinine to successfully treat 
children less than 13 years o f age with life-threatening, chloroquine-resistant malaria, 
confirmed the effectiveness o f quinine as a first-line drug for severe malaria in chloro­
quine-resistant areas o f sub-Saharan Africa (Greenberg et al. 1989b), and this has 
been reconfirmed more recently in studies in Liberia (Bjorkman et al. 1991) and 
Malawi (Wirima et al. 1990).
Drug efficacy studies: perinatal infection
Studies examined the W HO recommendation that served as the CCCD strategy 
from 1982 to 1986 for chemoprophylaxis in pregnant women: a treatment dose (25 
m g /kg  total dose) followed by low-dose chemoprophylaxis (5 m g /k g  weekly) with 
CQ (Steketee et al. 1987; Cot et al. 1992). Chemoprophylaxis was deemed neces-
10 Clinical failure refers to the persistence o f a measured axillary temperature o f  >37.5° C in a parasitemic child.




sary to keep the placenta parasite-free and thus reduce the risk o f LBW, a risk factor 
for infant death.
Showed that prophylaxis with CQ or pyrimethamine was ineffective in a setting where 
high levels o f resistance to these drugs had been documented. Chloroquine prophylaxis 
in pregnant women was extensively studied in Malawi, where CRPF had been con­
firmed in 1984. One study demonstrated that CQ  prophylaxis failed to maintain 
pregnant women free o f P. falciparum infection (M cDerm ott et al. 1988). In Kenya 
and other countries with similar resistance levels, the same finding held true (Steketee 
et al. 1987). As a result, chemoprophylaxis during pregnancy with CQ  was de­
emphasized as a recommended CCCD intervention.
In Nigeria in 1988, Nahlen and colleagues found that pyrimethamine chemoprophy­
laxis in either suppressive or causal prophylactic doses did not clear parasites from the 
blood o f pregnant women (1989); prophylaxis with pyrimethamine was therefore 
discouraged in Nigeria.
Documented that poor compliance is a major obstacle to the effectiveness o f chemopro­
phylaxis fo r  pregnant women. The decreasing levels o f CQ  efficacy were further com­
promised by low levels o f compliance to a weekly regimen of chemoprophylaxis. 
Even with CQ  available, few women in surveys in four countries (CAR, Liberia, 
Togo, and Zaire) were found to be complying with the recommended regimen of 
weekly CQ  prophylaxis. Data from Malawi also showed low rates o f compliance— 
36% o f the women in the study had urine CQ  metabolite levels compatible with reg­
ular compliance to the weekly CQ  dosage schedule, even when the drug was known 
to have been received by the women free o f charge (Heymann et al. 1990). Low lev­
els o f compliance reduced the effectiveness o f a chemoprophylaxis program for preg­
nant women.
Found alternative drugs effective in a program o f intermittent therapy or chemoprophy­
laxis fo r pregnant women. The MMRP found that M Q  in treatment (750 mg) fol­
lowed by weekly prophylaxis (250 mg) doses was far superior to treatment a n d /o r  
weekly prophylactic doses o f CQ  in clearing peripheral parasitemia and placental 
malaria infection and in reducing the frequency of LBW. However, M Q  did not 
meet one of the critical requirements for use in chemoprophylaxis programs: afford­
ability. More recently, a project in Malawi found that intermittent use o f two treat­
ment doses o f SP, one given at the first antenatal clinic visit and the second at the 
beginning o f the third trimester, linked to routine antenatal care, was effective in 
clearing peripheral and placental infections at the time o f delivery (Schultz et al. 
1993a). In addition, this regimen was more cost-effective than other alternatives in 
Malawi (Schultz et al. 1993b).
Drug sensitivity surveillance systems
Established national systems o f monitoring sensitivity «/Plasmodium falciparum to anti- 
malarials, thereby chronicling the spread o f CRPF across Africa. CCCD assisted partic­
ipating countries in establishing ongoing drug sensitivity surveillance systems. 
National or regional teams collected data at regular intervals on the parasite's 
response to CQ  and to second-line drugs, such as amodiaquine, SP, quinine, and
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MQ. Surveillance systems were established in 7 o f 12 malaria-endemic CCCD coun­
tries (CAR, Congo, Malawi, Nigeria, Rwanda, Togo, and Zaire), and sporadic testing 
using the CCCD protocol was done in Cote d'Ivoire, Guinea, Liberia, and Swazi­
land. These countries documented the progression o f CRPF across Africa, as well as 
within individual countries (Fig. 1-5).
Figure 1-5. T he Spread o f  C hloroquine-resistan t P. falciparum  M alaria in Africa
1978 1986 1993
Insecticide-impregnated bed nets
Found that insecticide-impregnated bed nets and curtains prevent malaria. Two studies 
in Kenya, a 4-month investigation in 1988 and a longer study starting in 1990, inves­
tigated the efficacy of permethrin-impregnated bed nets and curtains (Sexton 1990). 
Results showed that entomologic, parasitologic, and clinical indices improved with 
the use o f these mosquito barriers and confirmed findings from studies in The Gam­
bia (Alonso et al. 1993). During the low transmission season, bed nets offered 
greater protection against infection than curtains covering ceiling eaves, windows, 
and doors. During the season of high transmission, this protection may be less pro­
nounced; bed nets reduced the frequency of infection but did not prevent infection 
entirely (Beach et al. 1993).
Support Components
Surveillance and health information systems
O f the CCCD countries, Burundi, CAR, Malawi, Nigeria, Rwanda, Swaziland,
Togo, and Zaire established or improved a formal reporting system of disease surveil­
lance, which included routine reporting of malaria.
Collected data from hospitals that enabled many Ministries o f Health to monitor trends in 
diseases o f public health importance, including malaria. The countries mentioned 
above have developed the ability to monitor disease burden (number o f admissions, 
outpatient visits, CFRs) over time, increasingly with the use o f microcomputers.
Timely dissemination o f annual reports based on surveillance data enabled program man­
agers to design appropriate disease control strategies and operational research.
Bulletins and reports are being prepared within a few months after the end of a 
reporting period, rather than years later as occurred in the past. In 1989, in part as a
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result o f data from the national health information system in Malawi demonstrating 
the worsening malaria disease burden and low efficacy of existing programs, the 
national strategy was revised and treatment guidelines developed. Review of the sur­
veillance system in the Pediatrics Department o f the University Hospital Center in 
Lome, Togo, identified an association between malaria and anemia and led to a study 
o f the relationship between childhood malaria infection and anemia at St. Jean's 
Hospital in Afagnan. Hospitalized children less than 12 years o f age with parasitemia 
were more likely to have low hemoglobin concentrations, underscoring the impor­
tance o f anemia as a complication of malaria (Echitey, Aplogan, and Koumessi 1993).
Training and supervision
Improved diagnosis and treatment o f malaria at health facilities through training at the 
periphery o f the health care system, i.e., at the level o f first contact with the formal health 
care system. Initially, health facility assessments were carried out in all CCCD coun­
tries, and training was directed toward correcting the deficiencies identified in the 
needs assessments. Through the efforts o f the CCCD project, workers were trained 
to manage malaria patients by using standardized treatment algorithms (Fig. 1-6). 
Facility assessments demonstrated improvements in the diagnosis and treatment of 
malaria at all levels o f health delivery. The use o f injections to treat acute malaria ill­
ness dropped from 47% to 9%-28% in selected areas o f Togo after health workers 
underwent an intensive training and supervision program to provide oral antimalarial 
drugs (Fig. 1-7). Indices reflecting adequate provision o f services at the peripheral 
level should improve substantially with activities undertaken as a result o f the Malaria 
Initiative.
Figure 1-6. T reatm en t and  In fo rm atio n  Given to  M others o f  Febrile C hildren  
in R ural H ea lth  Facilities by P artic ipation  in  T ra in ing  in  C ôte d ’Ivoire, 1991







Côte d ’Ivoire, 1991: 38 observations in 15 facilities
Education regarding Prescribed Education regarding
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Figure 1-7. M alaria T reatm ent Practices w ith  Injections o r O ral D rugs, Togo, 1 983-1987







Published and distributed to health facilities newsletters designed to keep health profes­
sionals abreast o f current policies regarding disease treatment and prevention. The Cen­
tral African Republic published The DMPGE (Département de Médecine Préventive et 
Grandes Endémies) Echo, Zaire's publication was titled Sauvons nos Enfants (Let's 
Save Our Children), Burundi published Bulletin Epidémiologique de Burundi, and 
Nigeria named its publication Nigeria Bulletin o f Epidemiology.
Successfully employed the strategy o f Technical Cooperation between Developing 
Countries. To collect drug sensitivity data to be used in developing a national 
malaria strategy, CCCD national public health officials and microscopists went from 
Malawi to Swaziland and from Zaire to Guinea. National malariologists from Nige­
ria, Togo, and Zaire have served as malaria control consultants within Africa for 
W HO and for CDC. The CCCD program managers have become recognized as 
important authorities on malaria control in Africa by virtue o f the successful activities 
they conducted within their countries and the prominent roles they played regionally 
and internationally.
Health education
Conducted two 4-week intercountry workshops. The theme o f malaria control was 
selected by the African Regional Health Education Center (ARHEC) in Ibadan, Nigeria, 
in 1990 and by the School o f Public Health, University o f Kinshasa, Zaire, in 1991 for the 
annual short course in health education planning and management. Both workshops 
focused on planning a health education program based on the national malaria control 
strategies o f participants' countries.
The African Regional Health Education Center in Ibadan, Nigeria: The ARHEC 
workshop trained primary health care teams from four Local Government Areas 
(LGAs) in Nigeria and national personnel from Kenya, The Gambia, and Swaziland, 
receiving support from the CCCD Project. Health education plans were based on 
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vector control, and chemoprophylaxis o f pregnant women. In Nigeria, an interven­
tion and a control village in four LGAs were selected for pre- and postsurveys to eval­
uate the health education program. Each LGA site was visited by ARHEC staff, who 
assisted with implementation activities. One LGA (Ife Central) conducted both the 
pre- and postsurveys in the intervention and the control villages. Results in the inter­
vention village of Yekemi showed important changes in community knowledge and 
practices related to reducing the menace o f mosquitoes, the malaria control strategy 
selected for action by the LGA team in consultation with the villagers.
The School o f Public Health, University o f Kinshasa, Zaire (for francophone coun­
tries): The Kinshasa course emphasized integrating patient education and case man­
agement and evaluating the effect on compliance with the treatment regimen once 
the caretaker returned home. Participants from Zaire were health staff from the 
national and zonal levels; teams from Côte d'Ivoire, Madagascar, and Congo also 
attended the course. Training activities abruptly ended on September 23, 1991, 
when severe civil disorder erupted in Kinshasa. No follow-up activities were possible 
because the United States Agency for International Development (USAID) program 
in Zaire was terminated.
Trained health educators and social scientists in CAR, Côte d'Ivoire, Guinea, Nigeria, 
Rwanda, and Togo to conduct formative research as part o f malaria-related health educa­
tion program development. Results o f the research were used to prepare a quantitative 
survey instrument (Côte d'Ivoire); explore factors related to knowledge and behav­
ioral results o f a larger quantitative survey (Togo); assess community needs in malaria 
control (Nigeria); and define behavioral objectives for patient and community educa­
tion (CAR, Guinea, Rwanda).
Developed a prototype curriculum in 1992 that could be used at African national work­
shops to improve malaria case management through patient education. At a 2 -week 
workshop in Congo, consultants, including African malaria program managers, epi­
demiologists, health educators, and representatives from the African Regional Office 
o f W H O , A.I.D., and CDC, visited busy urban clinics, observed deficiencies in the 
patient education process, and demonstrated to clinic workers ways in which com­
munication with patients could be integrated into the case management process. 
Curriculum guidelines were then prepared on the basis o f workshop participants' 
experience in the clinics.
Logistics
Identified problems and potential solutions for shortages o f antimalarial drugs and diag­
nostic resources (e.g., thermometers and microscopes) in health facilities. Assessments 
o f health facilities in two areas o f Nigeria in 1991 revealed varying levels o f the avail­
ability o f drugs and diagnostic equipment. An assessment o f the 11 health facilities 
in Nsukka found that CQ  was not in stock at most facilities, and just over half the 
facilities had thermometers. Another assessment in the 13 health facilities in Barkin- 
Ladi found that all facilities had CQ  in stock, but that most had neither reagents nor 
supplies necessary for laboratory diagnosis o f malaria. Although early CCCD efforts
2 2
ACCOMPLISHMENTS
did not focus on this aspect o f the health system, later work emphasized logistics, 
which is key to implementation of any malaria control effort.
Evaluated the quality o f antimalarial drugs in one country. After low quality drugs were 
found in certain sectors in eastern Nigeria, evaluation of the quality o f antimalarial 
drugs was undertaken in conjunction with the National Malaria Control Program. 
Among over 100 preparations o f CQ  syrup bought on the commercial market, 34%- 
39% of the samples had inadequate amounts o f CQ  for therapeutic efficacy.
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S e c t i o n  III  
P r o g r e s s  T o w a r d  C C C D  T a r g e t s
The success o f CCCD's malaria component must be measured against the goals, 
objectives, and targets established for the CCCD project. The main goal o f the 
CCCD project was to help African nations improve the health o f their children by 
reducing morbidity and mortality caused by vaccine-preventable illnesses, diarrheal 
diseases, and malaria. In 1981-1983 objectives were established that focused on 
strategies to achieve this reduction in malaria-related morbidity and mortality: case 
management at home, in the community, and at health facilities and chemoprophy­
laxis for pregnant women. After several years o f field experience, targets were intro­
duced to m onitor and evaluate programs; these targets were revised periodically to 
reflect national, regional, and global experience.
Table 1-2. CCCD Malaria Objectives and Targets
Objectives Targets
Inpatient malaria mortality Reduce by 50%
H om e/com m unity treatment 50% correct treatment
Health facility management 90% correct management
Chemoprophylaxis for pregnant women N ot specified
Objective: To reduce inpatient malaria mortality by 50% 
Experiences:
Data from Malawi and Togo suggest that the proportion and number o f malaria- 
related inpatient deaths have risen (Figs. 1-8 and 1-9). Although surveillance has cer­
tainly improved, it is unlikely that these observations are due to improved reporting.
Figure 1-8. C hildren  U n d er 5 years, H osp ital D eaths due to  M alaria and  Anem ia,
M alawi, 1985-1 9 8 9
Percentage of hospital deaths 
50
Health Information System, MOH-M alawi, 1990
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Figure 1-9. Anemia and  M alaria D eaths, C hild  H ealth  U n it, Lom e, Togo, 1 985-1989








• The target o f a 50% reduction was not achieved. In fact, evidence suggests that 
malaria-associated mortality increased in a number o f the CCCD countries. 
There are several possible explanations for the reported increased malaria-associ­
ated mortality: (1) improved surveillance, although this was not the case with 
other conditions such as chicken pox or diarrheal disease; (2) increased malaria 
transmission, particularly in urban settings where populations are growing the 
fastest and where large hospital and attached clinic-based reporting may be the 
most developed; (3) poor response of the malaria parasite to CQ  treatment; (4) 
malaria-associated anemia that previously has not been recognized and managed 
as a malaria problem; and (5) inadequate therapy and consequent mortality as a 
result of poorly implemented case management strategy and unavailability of 
alternative drugs.
• During the CCCD Project, malaria control measures were introduced in chloro- 
quine-resistant areas. Earlier in the project, the progression of CRPF and efficacy 
of antimalarial drugs could not be measured because of the lack o f a surveillance 
system. In addition, programs and infrastructures for delivering treatment and 
prevention were not functioning effectively. Although improvements were made 
in recognizing the efficacy of CQ  and instituting rational treatment guidelines in 
many settings, they were not sufficient to prevent the increase in malaria-associ- 
ated morbidity and mortality.
Lessons Learned:
• In Africa, poor parasite response to the most widely available antimalarial drug 
has been a formidable obstacle in reducing mortality. This problem, as well as 
ineffective disease management in homes and health facilities, must be addressed 
to improve child survival.
Malaria [5 Anemia
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• Because malaria-associated anemia results in many deaths and requires a specific 
malaria control strategy, and because malaria transmission may be increasing in 
urban settings (where populations are increasing the fastest), local revisions o f 
urban control strategies will be required.
Objective: To achieve 50% correct treatment o f  febrile illness at home
or in the community.
Experiences:
• The frequency o f home treatment for febrile illness varied widely-8% in Rwanda, 
13% to 21% in two rural prefectures o f Guinea, 51% in Conakry (the capital o f 
Guinea), just over 25% in two health zones in Zaire, and 83% in Togo (Deming 
et al. 1989).
• In Togo in 1984, nearly all (97%) of those treated at home were treated within 
24 hours o f fever onset. The dosage of CQ , the antimalarial used by 94% o f the 
caretakers, was considered insufficient for more than 70% o f home treatments 
because less than 10 m g /k g  was given during the first full day o f treatment.
• In Conakry, Guinea, in 1986, 79% o f the febrile children were given antimalarial 
drugs by their caretakers; however, the dosage given at home was considered 
inadequate for 70% of those treated (Dabis et al. 1989).
• A 1992 Knowledge, Attitudes, and Practices study in Malawi showed that o f the 
caretakers who did not take their febrile child for treatment at a clinic, only 42% 
gave the child an antimalarial drug; o f the children who were given an antimalar­
ial, 91% were treated within 48 hours o f fever onset, as recommended. O f all 
febrile children not taken to a clinic, only 4.5% received optimal treatment, 
defined as proper age-specific dosage o f CQ  within 2 days o f fever onset (Slutsker 
et al. 1993b). Mothers with higher levels o f education were more likely to treat 
their children appropriately at home with an antimalarial drug or to take them to 
a health facility.
Conclusion:
Progress toward reaching the target o f appropriate treatment varied among the 
CCCD countries, depending on the extent o f coverage and the timing and amount 
o f drug administered. Many children were given treatment at home for their fevers, 
and in several areas, the proportion far exceeded the target o f 50%. The problem was 
that children often received insufficient dosages for their ages and weights, and thus 
their treatment was ineffective.
Lessons Learned:
• The CCCD Project gained considerable knowledge regarding behavior related to 
home antimalarial treatment. Although children received home treatment with 
an antimalarial drug for perceived febrile illness, the dosage given was not appro­
priate. Consequently, health educators must increase their efforts to address the 
issue of proper dosages for age or weight in young children.
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Posters and other forms of health education provide an important opportunity to 
communicate proper treatment to caretakers, and more culturally appropriate 
messages need to be designed, especially for women with no formal education. 
All example o f a successful health education message is the treatment chart devel­
oped by a Peace Corps volunteer in Malawi (Fig. 1-10). This poster was also 
incorporated into the packaging for CQ  by private sector pharmacists.
Figure 1-10. Malawi Peace Corps Chart

































Objective: To achieve 90% correct management o f  febrile illness
in health facilities
Experiences:
• Problems impeding malaria treatment in health facilities included limited avail­
ability o f drugs, improper dosage regimens, and lack of clear instructions for fol- 
low-up. Facility assessments in eight CCCD countries identified performance 
problems (Fig. 1-11), and one 1991 survey revealed that approximately three- 
fourths o f Côte d'Ivoire's health facilities had no CQ  (its first-line drug) in stock 
(Fig. 1-12).
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C ote d ’Ivoire, 1991
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Percentage of Febrile Children Given 
Treatment with Chloroquine 
N = 52
Facility assessment surveys, Côte d ’Ivoire, 1990
• Changes in health facility care were evaluated through repeat facility needs assess­
ments conducted in several countries. In the countries resurveyed, the quality o f 
care was shown to improve after training had been conducted (Fig. 1-13).
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Figure 1-13. Percentage o f  H ea lth  Facilities M eeting S tandards fo r M alaria Practices 
a t F irst and  Follow -up Visits, R w anda, 1987








Where training was provided, facility-based case management was improved. In facil­
ities where training was not conducted, case management remained unsatisfactory. 
Case management involves four major components: assessment, treatment, health 
education, and referral. In general, assessment was conducted in a standard fashion 
by recognizing fever or history o f fever; treatment was often not provided according 
to established guidelines (either because of poor health worker knowledge or lack of 
appropriate drugs); health education in general was poor; and referral criteria and 
conduct were not assessed. In countries where training was based on needs assess­
ments and quality was monitored, improvements were consistently observed.
Lessons Learned:
• In many facilities and community programs, the lack of antimalarial drugs such as 
CQ and SP was a barrier to treatment. Poor management and logistics weakened 
the ability o f facilities to provide appropriate treatment. Health facilities, espe­
cially those at the periphery, are dependent on adequate stores o f drugs and other 
needed supplies. These problems underline the urgent need to assess and 
improve the drug supply system in many countries.
• Since health staff and persons in communities preferred treatment practices o f the 
past, such as injections, efforts to improve and standardize treatment practices 
were hindered. Effective preservice and inservice training programs can improve 
quality o f care at health facilities, but unless the health system can ensure avail­
ability o f drugs, health facilities cannot provide quality services.
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1 9Objective: To implement CQ prophylaxis o f  pregnant women.
Experiences:
• Confirming earlier work done in The Gambia, studies in Zaire demonstrated that 
women in their first or second pregnancies were more likely to be parasitémie and 
more likely to deliver LBW babies (Steketee et al. 1988a).
• Studies demonstrated that regular treatment or chemoprophylaxis was important 
for malaria prevention in pregnancy because most parasitémie women were 
asymptomatic. Therefore, the use o f antimalarial drugs among only those women 
with signs and symptoms o f malaria illness would not treat the majority o f para­
sitémie women.
• Studies o f the efficacy o f CQ  demonstrated that P. falciparum was increasingly 
resistant to treatment doses (25 m g /k g  total dose) and low-dose chemoprophy­
laxis (5 m g /k g  weekly) (M cDerm ott et al. 1988).
• Finally, studies in Malawi demonstrated that poor compliance with CQ  prophy­
laxis (in a program where CQ  is given to the woman to take weekly at home) 
caused this already poorly effective drug to be o f little benefit in reducing malaria 
infection in pregnant women and reducing LBW in their babies (Heymann et al. 
1990).
Conclusions:
• Because o f drug resistance, poor compliance, and the consequent low program 
effectiveness o f CQ  chemoprophylaxis, this intervention was not stressed in the 
last years o f CCCD (1987-1993).
• Further studies were conducted to examine the actual benefit o f chemoprophy­
laxis as well as to examine more effective antimalarial drugs. The MMRP found 
that women in their first and second pregnancies were at greatest risk for malaria- 
associated LBW and therefore should be targeted for chemoprophylaxis. The 
MMRP also examined the effect on birth weight o f M Q, an antimalarial drug 
known to be effective; the use o f M Q  resulted in decreased incidence of LBW. 
These findings led to a study that tested a regimen that would be both affordable 
and practical to implement: intermittent treatment with SP, given under observa­
tion at first antenatal clinic visit (usually in the middle o f the second trimester) 
and again at the beginning o f the third trimester (with a minimum interdose 
interval o f 1 month) (Schultz et al. 1993a). This regimen proved to be affordable 
and effective not only in reducing the incidence o f placental malaria infection but 
also in increasing compliance. As a result o f these findings, the policy in Malawi 
has been revised. This regimen should be evaluated in other settings, and its 
implementation in Malawi and elsewhere must also be examined before it is rec­
ommended for use throughout the region.
12 The appropriateness o f  chemoprophylaxis for all pregnant women was called into question after a num ber of
studies were conducted and before targets were stated. N o target was specified for this objective.
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Lessons Learned:
• Drug sensitivity should be monitored to document changes in intensity o f para­
site resistance to drugs. Repeated monitoring in selected areas is more valuable 
than sensitivity testing performed only once in many areas.
• In areas with CRPF, i.e., the majority o f sub-Saharan Africa, the strategy of CQ  
chemoprophylaxis may no longer be appropriate and alternative drugs must be 
considered for malaria prevention. Where pyrimethamine is widely used (West 
Africa), current data suggest that it may offer limited benefit when used alone in 
a chemoprophylaxis regimen (Nahlen et al. 1989). Drugs that have been tested 
and shown to be efficacious include M Q  (Steketee et al. 1993a) and sulfa- 
pyrimethamine combinations (Greenwood et al. 1990; Schultz et al. 1993b); the 
sulfa-pyrimethamine combinations are currently the most affordable.
• A successful program of chemoprophylaxis among pregnant women must target 
women in their first or second pregnancies and provide high coverage during the 
season of high transmission (Steketee et al. 1993a).
• The program must also address the problem of low compliance, which is fre­
quently encountered when drug regimens require women to take the medica­
tions at home. A drug that would limit poor compliance, e.g., one with a long 
half-life such as SP, could be given as interm ittent treatment (shown to be effec­
tive with as few as two treatment doses in pregnancy) under supervision at clinics. 
Health education for pregnant women can improve compliance by stressing the 
need to visit antenatal clinics at least twice during pregnancy. Antimalarial 
chemoprophylaxis should be available through a program of antenatal care con­
venient for the pregnant women.
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S E C T I O N  IV
P r i o r i t i e s  f o r  M a l a r i a  C o n t r o l  i n  t h e  N e x t  D e c a d e
CCCD achievements and lessons learned have focused priorities for malaria control 
in sub-Saharan Africa in the coming decade.
Malaria imposes a great burden on the children and nations o f  this region. 
The impact o f  the disease cannot be ignored; it must be confronted.
• Malaria is one o f the major causes o f mortality among children less than 5 years 
o f age in sub-Saharan Africa. O f all children who become ill with malaria, 1% to 
2% will die from severe malaria. The human cost o f malaria-associated anemia in 
Africa is just beginning to be understood. Malarial anemia is associated with 10% 
to 30% o f in-hospital pediatric deaths and may be an important cause in up to 
75% o f malaria-associated pediatric deaths.
• Malaria exacts a tremendous economic toll on families and nations.
The epidemiology o f  malaria is now much better understood. At-risk persons 
are better identified, and coherent malaria control strategies have been devel­
oped; these must be implemented.
• The target groups are children younger than 5 years o f age and pregnant women. 
After the age o f 5 years, children begin to develop immunity that protects them 
from the most severe complications o f malaria infection. Pregnant women, espe­
cially those in their first, and possibly in their second, pregnancies, lose the 
immunity they have to adverse effects o f malaria infection and are susceptible to 
adverse consequences o f placental parasitemia.
• Case management is the prime focus o f control. Because o f extensive drug effi­
cacy testing, drug-resistance monitoring, and surveillance system development, 
more is known about which drugs are efficacious and what constitutes an effec­
tive dosage regimen.
Prompt case management with an effective antimalarial drug will reduce 
malaria-related morbidity and mortality. This case management strategy for 
acute m alaria/febrile illness in children must be implemented.
• At the outset, the strategy was to deliver a low dosage o f CQ  to at-risk groups. 
For children, the strategy was to treat individual cases o f malaria. Because o f the 
drug testing conducted and the surveillance systems established, the increase in 
C Q  resistance across Africa could be monitored, and alternative antimalarial 
drugs could be evaluated. Increasingly, in many areas, CQ  resolved neither the 
symptoms nor the parasitemia caused by malaria; furthermore, severely anemic
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children responded less well to CQ  than to SP. With this information, one coun­
try (Malawi) adopted a more effective first-line drug (SP) for acute illness. The 
strategy of prompt and effective treatment o f malaria/febrile illness has matured, 
and many countries are ready to take the next step o f implementing the strategy. 
The other components o f effective case management—accurate diagnosis, patient 
education, and proper referral—-need more attention and strengthening.
Data are now available to justify specific strategies to manage malaria in 
pregnant women and to manage its effects on the fetus and the newborn 
(perinatal malaria). Because pregnant women who become parasitemic are 
asymptomatic, either intermittent treatment or chemoprophylaxis is 
required. To be effective, the strategy chosen must be integrated into exist­
ing antenatal health programs.
• Control o f the effects o f antenatal and perinatal malaria proved to be a far greater 
challenge than anticipated, principally because of the ineffectiveness o f the drug 
recommended as prophylaxis during pregnancy. Pregnant women, especially in 
their first or possibly their second pregnancies, are susceptible to placental malaria 
infection, a risk factor for LBW, which in turn is associated with higher infant 
mortality. Poor compliance to weekly drug regimens limited the effectiveness of 
prophylaxis programs in pregnant women. CCCD activities found that a single 
dose of an effective drug at two clinic visits constitutes an effective strategy and 
reduces problems with compliance; this strategy should be used in antenatal 
health programs.
With improved case management strategies, acute illness and its potential 
progression to anemia can be managed. However, case management cannot 
prevent the initial infection. Because o f  the danger o f  repeated infections in 
children, there is a need to prevent mosquitoes from biting their young vic­
tims.
• Insecticide-impregnated bed nets have proven to be a promising method to 
decrease malaria-associated morbidity and mortality in settings o f low malaria 
transmission. This control method requires many technical, programmatic, and 
economic resources; therefore, bed nets should currently be used where experi­
enced technical groups and communities can properly support and maintain 
them. If further testing of the efficacy and effectiveness o f bed nets continues to 
show positive results, and if implementation plans can be developed, evaluated, 
and shown to be workable, bed nets should be recommended and promoted as 
an effective tool for malaria control.
A critical factor in malaria control is national health care leadership and 
infrastructure. National institutions must have clear and detailed written 
policies and plans that include management and logistics provisions to sup­
port malaria control within the country's borders.
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• The consequences o f  inadequate health infrastructures in C C C D  countries were 
evident: lack o f  antimalarial drugs in health facilities, limited surveillance, inef­
fective training program s, and inadequate disease surveillance and evaluation sys­
tems. M ost sub-Saharan African countries are currently trying to  resolve these 
problems. The national leadership m ust provide adequate resources to  ensure a 
viable infrastructure for the system to  work. C C C D  leadership in policy and p ro ­
gram m ing workshops initiated a process that many o f  the C C C D  countries have 
used and can continue to  use to  improve their national malaria policies, plans, 
and im plem entation.
Malaria control m ust link scientifically based strategies w ith  rational and fea­
sible operations.
• Case m anagem ent and prevention strategies using effective antimalarial drugs 
and control m ethods will decrease malaria m orbidity and mortality. However, 
continued m onitoring and evaluation o f those strategies m ust be undertaken to  
ensure that the m ost cost-effective approaches are being used. Malaria control is 
no t easy— the disease overlaps w ith many others, and its control requires a tten ­
tion to  behavioral, biologic, clinical, and epidemiologic issues. A malaria vaccine 
is still no t available, bu t remains on the horizon. Thus, operational research tied 
to  field operations will remain an im portant priority for countries and for interna­
tional agencies com m itted to  malaria control in Africa.
The priority for the 1 9 90s is to  translate the lessons learned and the infor­
m ation gained into action. A  critical feature o f  this action w ill be the docu­
m entation o f  the effect o f  control actions on malaria-related m orbidity and 
mortality.
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I N T R O D U C T I O N
In t r o d u c t i o n  t o  P a r t  T w o
The purpose o f Part Two, "CCCD  At W ork in Sub-Saharan African Countries," is to 
provide a summary o f malaria com ponent activities over the course o f  these nations' 
involvement in the C CC D  project. Some countries took  part for a few years, others 
for almost a decade. All made strides in com batting malaria-by creating and 
strengthening malaria units and leadership; by developing, prom ulgating, and refin­
ing policy; by gaining a greater understanding o f current attitudes and practices; by 
helping define appropriate case m anagem ent and prevention strategies; by m onitor­
ing the spread o f drug  resistance across Africa; and by building national capacity to 
deliver malaria treatm ent and prevention programs.
The inform ation was compiled from the archives o f  the Malaria Branch, National 
Center for Infectious Diseases, Centers for Disease C ontrol and Prevention (C D C ), 
and o f the International H ealth Program Office, C D C , as well as from publications. 
Additional inform ation resides with individual researchers and governm ent and m in­
istry offices. This summary is by no means comprehensive, bu t, as nearly as possible, 
is intended to  outline the major malaria-related activities in participating countries. 
Com m ents and additions from readers will be welcome.
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Country Data
Population (1991): 5,700,000 
% infants with low birth weight (LBW) (1980-1988):
9 (Bujumbura only)
Infant mortality rate (1991): 108/1000 
Under-5 mortality rate (1991): 181/1000 
Annual number of under-5 deaths (1991): 47,000 
Total fertility rate (1991): 6.8
Years o f CCCD Involvement: 1985-1993
National Organization and CDC Resident Staff
National CCCD Program Director:
Dr. Fidele Bizimana 
National Malaria Coordinator:
Dr. Hilaire Ndihokubwayo 
Technical Officers:




Belgian Technical Assistance for Burundi, Fonds Européen pour le développement, United 
Nations Fund for Population Activities, United Nations Children's Fund (UNICEF), 
United States Agency for International Development (A.I.D.), World Health Organization 
(W HO)/Global Programme on AIDS, World Bank
N O T A B L E  C C C D  ACTIVITIES  IN B U R U N D I:  M A L A R IA
Malaria Policy and Program Development
Written CCCD malaria policy approved: 1988 
Malaria coordinator named: 1988
Operations Research
Drug Studies (in vivo testing by national or international teams)
1989
• Conducted a study of in vivo responses of P. falciparum to chloroquine (CQ) and sulfa- 
doxine-pyrimethamine (SP) in Nyanza Lac
Health Unit Practices Surveys 
19 87
Carried out needs assessment in Ngozi Region to determine quality of health worker care of 
malaria patients
• Over a third (35%) weighed child
• 67% took temperature
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• More than 7 in 10 (71%) children treated at center
• 0-5% educated the mother regarding follow-up treatment
• Nearly half (49%) of those given antimalarials received correct treatment
1989
Conducted survey of malaria treatment practices by health workers in 65 health centers
• Identified problems in knowledge (25% of health facilities) and irregular supplies of CQ 
(22% of health facilities)
• 75% of nurses knew national strategy for the treatment of febrile episodes with CQ
• Proportion of children without fever having parasitemia varied from 0% at high eleva­
tions to 69% in the southern plain area of the country (Fig. 2-1)
• Identified high-risk malaria areas
• Found significant differences in prevalence of parasitemia: parasitemia primarily a prob­
lem in low-lying inland areas and the lakeshore area of the country; malaria control activ­
ities then intensified in these areas
1987
• 8% of 3,456 children younger than 5 years of age had a fever in the 4 weeks prior to the 
survey
• Nearly 50% of febrile children went to a health center
• Approximately 20% were given antimalarials
• 22% of febrile children did not receive any treatment
Other Malaria-related Activities
1986
• 4 staff members taught in vivo drug testing in Côte d'Ivoire during CCCD training 
workshop
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1988-89
• CCCD assisted the Ministry of Health (MOH) in the first decentralized, integrated 
microscopy training program; 22 technicians trained in malaria diagnosis
• Job Aids developed for malaria
1989-90
• Documented increased malaria morbidity, mortality, and case-fatality rates (CFRs)
1990-91
• Provided 60 microscopes; microscopists trained in 9 health sectors; 13 supervisors 
trained in microscopy
• Each of the health centers in highly malaria-endemic health sectors had a trained micros- 
copist and a microscope
• Revised set of Job Aids (Fiches techniques) on malaria completed, printed, and made 
available
1992
• National epidemiologic and statistical unit created
1993
• Published quarterly feedback bulletin 
1989-93
• Disease reporting system operational in Burundi
S e l e c t e d  R e f e r e n c e s
Coosemans, M. 1990. From epidemiological research on malaria to an operational control 
program: exemplified by a project in Burundi [French], Ann Soc Belg Med Trop. 70 Suppl 
1:34-5.
Coosemans, M. 1991. Going into the 21st century: should one dream or act? [French]. Ann 
Soc Belg Med Trop. 71 Suppl 1:7-16.
Coosemans, M.H. and Nguyen-Dinh, P. 1985. Evaluation of antimalarial drugs in a region 
with a high prevalence of chloroquine-resistant Plasmodium falciparum (Burundi, Central 
Africa) [French]. Ann Soc Belg Med Trop. 65 Suppl 2:115-21.
Coosemans, M. and Barutwanyo, M. 1989. Malaria control by antivectorial measures in a 
zone of chloroquine-resistant malaria: a successful programme in a rice growing area of the 
Rusizi valley. Trans R Soc Trop Med Hyg. 83 Suppl:97-8.
Laroche, R , Coosemans, M., Floch, J.J., and Ndabaneze, E. 1988. Current strategies in the 
campaign against Plasmodium falciparum malaria in an area resistant to 4-aminoquinolines 
[French]. Med Trop (Mars). 48:133-8.
Ministère de l 'Intérieur, Département de la Population, Gitega, Burundi, and Demographic 
and Health Surveys, Institute for Resource Development/Macro Systems, Inc. 1988. 
Enquête Démographique et de Santé au Burundi, 1987. Columbia (MD): Demographic 
and Health Surveys, Institute for Resource Development/Macro Systems.
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C E N T R A L  A F R I C A N  R E P U B L I C
Country Data
Population (1991): 3,100,000 
% infants with LBW (1990): 15 
Infant mortality rate (1991): 106/1000 
Under-5 mortality rate (1991): 180/1000 
Annual number of under-5 deaths (1991): 25,000 
Total fertility rate (1991): 6.2
Years o f CCCD Involvement: 1984-1992
National Organization and CDC Resident Staff
National CCCD Program Directors:
Dr. Jean Limbassa, Dr. Jean Baptiste Roungou 
National Malaria Coordinators:
Mr. Madji, Dr. Fleurie Mamadou-Yaya,
Dr. Dieudonné Yazipo 
Technical Officers:
Dr. Katherine Montgomery, Mr. Joe Naimoli,
Ms. Karen Hawkins Reed 
Regional Epidemiologists:
Dr. Melinda Moore, Dr. Ronald Waldman
Major Donors
A.I.D., European Community (EC), Fonds d'Aide et de coopération (FAC), UNICEF, 
WHO
N O T A B L E  C C C D  ACTIVITIES  IN 
C E N T R A L  A F R I C A N  R E P U B L I C :  M A L A R IA
Malaria Policy and Program Development
Written CCCD malaria policy approved: 1986 
Malaria coordinator named: 1987
Operations Research
Drug Studies (in vivo testing by national or international teams)
1984-1986 
See Table 2-1
Table 2-1. Selected Results of In Vivo Testing, 1984-1986
Year Location Participants CQ Dosage Resistance Level (#)
1984 Bangui 31 asym ptom atic  schoo lch ild ren 10 m g/kg R I(1), RII (1)
Bangui 14 febrile ch ild ren 25 m g/kg n o n e
1985 Bangui 29 asym ptom atic  schoo lch ild ren 10 m g/kg n o n e
Bangui 43 febrile ch ild ren 25 m g/kg R i ( i )
1986 Bouar 25 febrile ch ild ren 10 m g/kg RI (1), RII (5)
Bouar 34 febrile ch ild ren 25 m g/kg n o n e
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1986
• 57 febrile children treated in Bambari showed low levels of resistance to falciparum para­
sites; 3 cases of RI level resistance; none had clinical signs by Day 7
1988
• Identified low levels of CQ resistance through local in vivo testing
• 2 regions (Nola, Health Region 2 and Bossangoua, Health Region 3) completed in vivo 
resistance studies; 3 cases of RI or RII of 63 in vivo tests in Nola; 1 case of RI of 63 in 
vivo tests in Bossangoua
1991
• Resistance to CQ in 1989, 1990, and 1991 was less than 20%; no cases of RIII were 
found
1992
• Conducted a study comparing the antimalarial efficacy of CQ and SP in children less 
than 5 years of age with microscopically confirmed P. falciparum at the pediatric unit of 
the University Hospital; children treated with SP were more likely to achieve parasito­
logic cure and had higher hemoglobin concentrations than those treated with CQ
Drug Sensitivity Surveillance System (7-day in vivo testing)
1985
• Established sentinel sensitivity surveillance system
1987
• Performed large resistance study using regional in vivo surveillance network
Other Studies
1986
Retrospective study of birth weights outside Bangui
• An average of 18%-24% of all newborns were LBW
• Average newborn weight was 2,837 grams
• Findings called for further study to determine whether malaria was a contributing factor 
to the high incidence of LBW babies
1988
Conducted retrospective study of hospitalized cases and deaths due to malaria among chil­
dren less than 15 years of age in the pediatrics complex of the National University Hospital
in Bangui
• Malaria CFRs rose from 1987 to 1988
• The number of deaths due to malaria, although small in number, increased from 1987 to 
1988
1992
Conducted 2 field surveys of Bangui pharmacists regarding recommended treatment sched­
ules for febrile children
• First survey, prior to the national malaria symposium with physicians and pharmacists, 
found that none of the recommendations made by pharmacists corresponded to the 
national malaria policy
• Second survey found that less than half complied with the policy
Conducted a nationwide "willingness to pay" survey
• Vast majority paid for antimalarials in the past and were willing to pay in the future
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Knowledge, Attitudes, and Practices (KAP) Surveys
1985
Conducted surveys in Bangui and Bambari of mothers and health personnel
• The majority of mothers cared for febrile children at home before going to clinic
• Proportion of pregnant women using chemoprophylaxis varied: 55% in May, 36% in 
November
• Health workers generally knew what to do, but were deficient in history-taking and 
physical examination
• Health workers prescribed a great variety of dosage regimens
1992
Conducted a national survey of febrile children and pregnant women in 580 households
• 20% of mothers took their febrile children to a health facility
• 76% treated the children at home
• A great majority (87%) of mothers who treated their children at home gave them CQ 
tablets
• Mothers generally started to treat fever during the first day
• Most women did not know the effect of malaria on their pregnancy, but knew that CQ 
prophylaxis would be helpful
• Most pregnant women took the correct dosage of CQ, but a number took too much or 
too little
Health Unit Practices Surveys
1986
Evaluated 4 hospitals
• All followed national protocols in the management of malaria cases
1988
Surveyed performance of health personnel in 2 regional hospitals, 1 prefectural hospital, and 
8 outpatient facilities
• Found performance in applying the national malaria policy far below minimum levels of 
acceptable practice
• 1 in 11 facilities used the correct dosage of CQ
Pretested a health facility survey in 11 hospitals and rural health facilities in 2 different 
regions
• Only one facility recommended treatment according to the dosage protocol
• Most facilities were following guidelines for pregnant women
• About 50% prescribed prophylactic doses for children younger than 5 years of age
1990
Assessed malaria treatment practices among 87 health workers
• Found wide range of performance problems: most facilities had basic supplies, most 
workers verified the presence of fever and treated with CQ as the drug of choice, but 
other elements of effective case management were either omitted or performed incor­
rectly
• Health workers did worse in the areas of health education and promotion of malaria pro­
phylaxis, with generally fewer than half meeting criteria
• Training and health education materials developed to improve patient education
4 9
C E N T R A L
A F R I C A N  R E P U B L I C
Other Malaria-related Activities
1985
• 4 staff members trained to perform in vivo drug response testing in Zaire during CCCD 
training
1988
• Sentinel surveillance system established
• Prepared and distributed to health workers appropriate treatment recommendations and 
national policies based on studies conducted
• Developed preliminary training materials for use in 1989 in-service training program for 
case management
1989
• Malaria CFRs at 4 sentinel hospitals showed increases: from 3.0 per 100 admissions in 
1987, to 4.1 in 1988, and to 7.0 in 1989
• Approximately 31% of children younger than 5 years of age had access to CQ in govern­
ment and private health centers
• Developed a system for distribution of antimalarials
• Malaria, as well as other CCCD target diseases, reported monthly from 15 regional and 
prefectural hospitals (sentinel sites)
• Feedback bulletin first published
• National hospital surveillance system established and case definitions approved for 
reportable diseases
1990
• Malaria CFR of 5% seen in 15 regional and prefectural hospitals in the sentinel system
• Health information system (HlS)-generated data on in vivo response to antimalarials 
contributed to the development of national malaria treatment policy
• Produced training manual on malaria prevention and treatment, which was based on 
results of health worker practice evaluation
• 3 issues of The DMPGE (Departement de Médecine Preventive et Grandes Endémies) 
Echo, an epidemiology newsletter, published and distributed to program managers and 
health workers
1991
• Developed a malaria training manual for 1991 training programs; refined in 1992
• Trained over 500 health agents in the proper case management of malaria among febrile 
children and malaria prevention among pregnant women
1992
• Participated in a regional workshop on the revision and refinement of the national 
malaria policy; after the workshop, refined national malaria policy addressing the proper 
case management of fever and malaria; policy then signed by the Minister of Health
• Conducted a national symposium to communicate to approximately 200 physicians and 
pharmacists the national policy on recommended treatment protocol for malaria, includ­
ing proper case management and prevention for pregnant women
• Participated in a regional workshop on the development of national malaria control pro­
grams
• Refined national program after the workshop
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Country Data
Population (1991): 2,300,000 
% infants with LBW (1990): 16 
Infant mortality rate (1991): 83/1000  
Under-5 mortality rate (1991): 110/1000  
Annual number of under-5 deaths (1991): 11,000 
Total fertility rate (1991): 6.3
Years o f CCCD Involvement: 1984-1987
National Organization and CDC Resident Staff
National CCCD Program Director:
Dr. Gabriel Madzou 
National Malaria Coordinators:
Mr. Henri Moudzeo, Dr. Gaston Samba 
Technical Officers:
Dr. Pierre Eozenou (FAC), Mr. Brian Fitzgibbon, 
Ms. Karen Hawkins Reed 
Regional Epidemiologists:
Dr. Melinda Moore, Dr. William Taylor
Major Donors
A.I.D., FAC, UNICEF
N O T A B L E  C C C D  ACTIVITIES  IN CON GO : M A L A R IA
Malaria Policy and Program Development
Written CCCD malaria policy approved: 1986 







Table 2-2. Results of In Vivo Testing, 1985-1986
Location Drug resistance (%)
10 m g/kg CQ 25 m g/kg CQ 25 m g/kg AQ
Linzolo 20.0 n.t.j n.t.
Brazzaville 59.1 40.0 26.3
Mayombe 74.1 28.8 n.t.
Chaillu 57.1 38.7 n.t.
Brazzaville n.t. 38.7 21.2
* AQ = Amodiaquine 
t n.t. = Not tested
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Drug Sensitivity Sur\>eillance System (7-day in vivo testing)
1985
• Established CQ sensitivity monitoring surveillance system 
Knowledge, Attitudes, and Practices (KAP) Surveys
1985
• Between 65% and 90% of febrile children received CQ
• Approximately 20% were underdosed
Clinic-based Surveys
1985
Surveyed 61 mothers or caretakers in Brazzaville
• Nearly 40% of children had received some treatment before coming to clinic
• 21.3% were given injectable quinine
• A wide range of doses prescribed, but all were within therapeutic limits 
Small survey reported that 9% to 20% of malaria cases in children treated correctly 
By 1985, 51% of pregnant women received regular prophylaxis
1986




• 4 staff members taught in vivo drug response testing in Zaire to monitor resistance lev­
els; they helped establish national drug sensitivity testing network
• Trained regional health workers using model CCCD training guides and WHO training 
materials; regional teams developed action plans for malaria activities, as well as other 
CCCD interventions
1986
• 3rd CCCD Consultative Meeting held in Brazzaville, followed by CDC-sponsored 2- 
day workshop on drug testing
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C O T E  D'IVOIRE
Country Data
Population (1991): 12,500,000 
% infants with LBW (1990): 14 (Abidjan only)
Infant mortality rate (1991): 93/1000 
Under-5 mortality rate (1991): 127/1000 
Annual number of under-5 deaths (1991): 77,000 
Total fertility rate (1991): 7.4
Years o f CCCD Involvement: 1985-1992
National Organization and CDC Resident Staff
National CCCD Program Directors:
Mr. L. Bla Toh, Dr. Estelle Shaw 
National Malaria Coordinators:
Dr. Amananman, Dr. Guy Imbua-Bogui,
Dr. Jean Niangue 
Technical Officers:
Mr. James Herrington, Mr. Robert Weierbach 
Field Epidemiologists:
Dr. Cornelia Davis, Dr. Ronald Waldman
Major Donors
A.I.D., FAC, International Development Research Center (IDRC), Overseas Development 
Agency (ODA), UNICEF
N O T A B L E  C C C D  ACTIVITIES IN C O T E  D'IVOIRE: M A L A R IA
Malaria Policy and Program Development
Written CCCD malaria policy approved: 1986 
Malaria coordinator named: 1985
Operations Research
Drug Studies (in vivo testing by national or international teams)
1986
Conducted a study of 109 children 6 months to 5 years of age in 2 rural areas (Adzope and 
Bouafle)
• P. falciparum sensitive to 10 m g/kg of CQ
Conducted a study of 96 children 5 to 15 years old near Abidjan
• 10 m g/kg of CQ effective, as was 200 mg of amodiaquine (AQ)
Drug Sensitivity Surveillance System (7-day in vivo testing)
1987
• Periodic sensitivity studies undertaken by the National Public Health Institute
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Health Unit Practices Surveys 
1986
Conducted a survey in 140 health facilities
• Found that fewer than half (48%) prescribed the correct dose of CQ for a 2-year-old 
child
• CQ prophylaxis was prescribed for pregnant women by 9 of 28 practitioners
• 48% of health facilities using CQ provided an acceptable dose
• 27% of facilities providing chemoprophylaxis used the WHO-recommended dose of 300 
m g/kg
• 86% recommended chemoprophylaxis to pregnant women
Surveyed 64 doctors and nurses in Abidjan
• 44% used CQ as the primary treatment drug
• Found that none gave 25 m g/kg of CQ
1990
Conducted survey of health worker performance and logistics support at 41 health facilities;
interviewed 320 children and mothers; survey provided basis for planning training activities
• 42% of facilities surveyed had CQ in syrup or tablet form in stock, ranging from 75% of 
base facilities to 20% of dispensaries
• Fewer than half the mothers of children diagnosed with fever were told when they 
should return with the child; 60% of health workers explained the administration of CQ 
to mothers; only 1 in 10 told the importance of completing the treatment course
• O f the 86 diagnosed febrile children, 83% of mothers received a prescription for an anti- 
malarial
1991
Trained health personnel in the 41 facilities surveyed in 1990 and evaluated the training
• Observed an increase in education about how to administer medicines and about the 
need for 3 days of treatment
Other Malaria-related Activities
1986
• Held seminar on drug sensitivity testing for participants from Côte d'Ivoire, Guinea, 
Burundi, and the Organisation de Coopération et de Coordination pour la lutte contre 
les Grandes Endémies
1988
• Yamoussoukro site of fourth CCCD consultative meeting, March 1988
1989-90
• National disease reporting system operational; data generated from drug sensitivity test­
ing used to contribute to national malaria treatment strategies
• Developed and distributed 2 versions of malaria treatment poster that emphasized use of 
CQ in dosage of 25 m g/kg over 3 days
1990
• Sentinel surveillance project implemented in 5 geoclimatically representative sites
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1990-91
• Developed training model to achieve systematic in-service training of peripheral health 
workers by district staff members; training strategy based on health facility needs assess­
ments; 8 of the 26 health districts held peripheral courses
• Developed and field-tested training materials (technical handouts)
• Printed and distributed malaria treatment chart developed by MOH and private sector
• Provided 10 microscopes to 5 urban health centers and trained 14 staff members to 
examine thick and thin blood smears
1992
• As part of Malaria Control Initiative, held 10-day workshop, "Intercountry Workshop 
on Program Planning and Management for Malaria Control"; 35 participants from 17 
francophone African countries attended, along with participants from WHO/African 
Regional Office and W HO/Geneva; each country drafted a national program plan
S e l e c t e d  R e f e r e n c e s
Bachschmid, I., Soro, B., Coulibaly, A., Philippe, E., Kingston, L., Kien, T., and Rey, J.L. 
1991. Malaria infection during childbirth and in newborns in Becedi (Côte d'Ivoire) 
[French]. Bull Soc Pathol Exot Filiales. 84:257-65.
Glik, D., Ward, W., Kouame, K., and Guessan, M. 1987. Focus group methods for formative 
research in child survival: an Ivoirian example. International Quarterly of Community 
Health Education 8(4):297-316.
Khantaway, K. 1986. Health facilities survey in Côte d'Ivoire [thesis]. Atlanta: Emory 
School of Medicine, 1987.
N'Guessan Diplo, L., Rey, J.L., Soro, B., and Coulibaly, A. 1990. Infant mortality and its 
causes in a sub-district of Côte d ’Ivoire [French]. Med Trop (Mars). 50:429-32.
Soro, B., Davis, C.E., Peyron, F.M., Yao, F., Saki, Z.M., Nguyen-Dinh, P., and Breman, J.G. 
1989. Formulation of malaria treatment policy for children in Côte d'Ivoire as chloroquine 
resistant Plasmodium falciparum spreads into West Africa. Ann Trop Med Parasitol. 83:101- 
6 .
5 9
G U I N E A
G U IN E A
Country Data
Population (1991): 5,900,000 
% infants with LBW (1990): 21 
Infant mortality rate (1991): 138/1000 
Under-5 mortality rate (1991): 234/1000 
Annual number of under-5 deaths (1991): 71,000 
Total fertility rate (1991): 7.0
Years o f CCCD Involvement: 1985-1991
National Organization and CDC Resident Staff
National CCCD Program Directors:
Dr. Souleymane Diallo, Dr. Fassou Haba,
Dr. Moussa Keita 
National Malaria Coordinator:
Dr. Moussa Keita 
Technical Officers:




A.I.D., UNICEF, World Bank
N O T A B L E  C C C D  ACTIVITIES  IN G U IN E A :  M A L A R I A
Malaria Policy and Program Development
Written CCCD malaria policy approved: 1988 
Malaria coordinator named: Prior to CCCD
Operations Research
Drug Studies (in vivo testing by national or international teams)
1989
Carried out first in vivo studies of antimalarial resistance with assistance from CCCD/Zaire
• Failed to document evidence of CQ resistance in Kindia
• Showed that 67% of the 766 children examined were slide positive for malaria
1990
Conducted a study in Conakry of 39 children who were treated with 25 m g/kg of CQ over 
3 days
• Dosage was effective; children were free of parasites at day 7 
Conducted a study in Conakry of 923 children
Testing without outside help confirmed lack of CQ resistance
• Found that half were slide positive for malaria
• With treatment, children had no parasites at day 7
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Other studies 
1986
Assessed effect of malaria control measures on parasitemia during pregnancy among 948 
pregnant women in Conakry
• None of the women taking an antimalarial were parasitemic; 7% of those who did not 
take an antimalarial were parasitemic
• No correlation was found between recent history of fever and parasitemia
Knowledge, Attitudes, and Practices (KAP) Surveys
1985
Conducted a study of treatment of fever in 2 prefectures
• In Dinguiraye Prefecture, 6% of febrile children were seen at a health center; 13% were 
treated with an antimalarial drug at home
• In northern Dabola Prefecture, 17% of febrile children were seen at a health center; 21% 
received treatment with an antimalarial at home
1988
Conducted a community survey in Kindia and Telimele of 243 mothers in rural and urban 
areas
• 39% of urban and 22% of rural women took CQ during their most recent pregnancy
• Use of drugs related to access and availability factors, including perceived nearness of 
health facility, perceived use of CQ by others, and affordability of drugs
• Documented differences in CQ use for fever in urban vs rural areas: 67% in urban areas 
treated fever with CQ, and 40% in rural areas used CQ for fever
Health Unit Practices Surveys
1986
Health practices survey methodology developed and field tested in Conakry; assessed health 
practices of 1,415 caretakers and their 2,048 children (Fig. 2-2)
• In 20% of cases the caretaker ascribed the fever to malaria
• 43% of febrile children were taken to a health worker
• Nearly three-fourths (74%) of children taken to health worker within 48 hours of fever 
onset
• Use of injectable antimalarials and prolonged treatment with CQ were common at 
health facilities
• 79% of febrile children were treated at home
61
G U I N E A
Figure 2-2 . Treatment Scheme for Children with Fever, Conakry, 1986
Reproduced, by permission o f  the W orld Health Organization, Geneva, from: Bulletin o f the World Health Orga­
nization, 67: 681 (1989).
1988
Health center needs assessment conducted in Conakry by direct observation of health work­
ers' management of febrile children
• Nearly all (98%) febrile children weighed
• 73% given an antimalarial
• 16% given the correct dose of antimalarial
1989-90
Assessed health worker practices in rural areas of Telimélé prefecture
• Approximately half of febrile children weighed
• Approximately 80% of cases prescribed CQ
1990
Conducted a record review of Conakry health care centers
• With a national policy prescribing 25 m g/kg during 3 days, physicians continued to pre­
scribe a number of drugs, including injectable quinine
• 80% of fever cases treated with appropriate therapy
Other Malaria-related Activities
1986
• CCCD/Guinea malaria program staff members trained to conduct in vivo testing during 
Côte d'Ivoire study and training exercise
1987
• Developed monthly case reporting forms and CQ inventory forms
1988
• Training needs assessments identified specific needs for training in malaria; health educa­
tion materials (3 posters) developed to strengthen patient education
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• 20 malaria control technicians participated in training course in malaria slide microscopy 
and in vivo drug sensitivity testing
1989
• Health educators and social scientists trained to use formative research methods, includ­
ing ethnography, to plan health education programs dealing with presumptive treatment 
of children <5 years of age and chemoprophylaxis for pregnant women
• Zairians trained by CDC in in vivo testing provided training and expert consultation to 
Guinea
• Established a distribution system for CQ, including inventory, distribution, reporting, 
and financial accountability
• Established sentinel surveillance system
• Instituted cost recovery system in Kindia and Telimele; revenues from sale of CQ tablets 
used for local recurrent costs
S E L E C T E D  R E F E R E N C E S
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LIBERIA
Country Data
Population (1991): 2,700,000 
% infants with LBW: data not available 
Infant mortality rate (1991): 131/1000 
Under-5 mortality rate (1991): 200/1000 
Annual number of under-5 deaths (1991): 25,000 
Total fertility rate (1991): 6.8
Years o f CCCD Involvement: 1983-1990
National Organization and CDC Resident Staff
National CCCD Program Directors:
Dr. Wilhelmina Holder, Mrs. Eugenia Kromah,
Dr. Rose Macauley 
National Malaria Directors:
Mrs. Koh Margaret Korpor, Mr. Benedict Mason 
Technical Officers:
Dr. Barbara Maciak, Mr. James Thornton
Major Donors
A.I.D., Christian Health Association of Liberia, Peace Corps, Plan International, Rotary 
International, South Eastern Regional Primary Health Care Project, UNICEF, WHO
N O T A B L E  C C C D  ACTIVITIES  IN LIBERIA: M A L A R I A
Malaria Policy and Program Development
Written CCCD malaria policy approved: 1987 
Malaria coordinator named: 1985
Operations Research
Drug Studies (testing by national or international teams)
1988
• CQ-resistant malaria documented in Zorzor, Lofa County
• Documented low rates of P. falciparum parasitemia among 400 children in Monrovia 
area
• In vitro studies at Elwa Hospital confirmed CQ resistance 
Demographic and Health Sur\>ey (DHS)
1986
• Over half (51%) of 4,224 children less than 5 years of age had one or more episodes of 
fever in the month preceding the survey
• 74% of childhood fever cases treated with antimalarials
• Prevalence of fever highest (67%) among children aged 12-17 months
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Health Unit Practices Surveys
1986
Reviewed practices in 11 health facilities
• More than 80% were using a treatment regimen consistent with the new policy
• Approximately 70% were providing prophylaxis to pregnant women
1989
Assessed health worker performance, including communication practices of health workers, 
at 45 facilities in 6 counties
• Excessive use of injections for malaria treatment identified as performance problem 
(nearly half of health workers gave an initial injection with CQ)
• Although most health workers reportedly advised mothers to give CQ for 3 days, exit 
interviews of mothers showed a lack of understanding
• CQ treatment charts available in only 3 of 10 clinics; SP, second-line drug, available in 
only 3 of 45 facilities
• Malaria supplies in stock in 45 facilities; CQ tablets in over 90%; CQ syrup in over 80%
1990
• Conducted survey of malaria treatment practices among pharmacists and medicine store 
dispensers; because of civil war, CCCD staff evacuated before data entered and analyzed
Mortality and Use of Health Services Surveys (MUHS)
1984-85
• Conducted MUHS surveys and reinterview surveys 
1988
Repeated MUHS surveys
• Showed 14.5% decrease in under-5 mortality
• Little change found in home treatment for malaria/febrile illness (69% in 1984; 67% in 
1988)
• Showed 80% of febrile children, more than half of whom were treated at home, given 
"Western" medicine
• Approximately 7 in 10 febrile children less than 5 years of age received an antimalarial in
1984 and 1988
• The proportion of febrile children who visited a clinic or a hospital fell from 41% in 1984 
to 24% in 1988
• Home treatment with CQ increased from 4.5% in 1984 to 35% in 1988
Other Malaria-related Activities
1987
• First quarterly newsletter produced and distributed
• Trained 4 national staff in methodology of in vivo monitoring of CQ resistance
1987-88
• Radio messages, songs, and dramas on malaria modified and produced
1988
• 4 Liberians trained in Nigeria to perform in vivo testing for P. falciparum drug resistance
1988-89
• Malaria treatment poster developed and tested
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• Computerized hospital sentinel surveillance system established in 5 hospitals; data col­
lected on pediatric morbidity and mortality (Fig. 2-3)
_____________Figure 2-3. Pediatric Admissions and Deaths in 5 Sentinel Hospitals___________
Admissions Deaths
Anemia 21% ARI^36%
*NNT = Neonatal tetanus 
tARI= Acute respiratory infection
• Developed prototype of computerized hospital morbidity reporting system
1989
• Participated in WHO Intercountry Workshop on Regional Malaria Control Strategies 
for Primary Health Care in Monrovia; developed draft protocol for diagnosis and clinical 
management o f malaria at community, clinic, and hospital levels
• Revised malaria training modules and health education materials
1989-90
• Malaria standard 3-day CQ (tablets and syrup) treatment charts revised and field-tested
• Sentinel disease surveillance system established at 6 hospitals
S E L E C T E D  R E F E R E N C E S
Bureau of Statistics, Ministry of Planning and Economic Affairs, Monrovia, Liberia, and 
Demographic and Health Surveys, Institute for Resource Development/Macro Systems, 
Inc. 1988. Liberia Demographic and Health Survey, 1986. Columbia (MD): DHS, IR D / 
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Country Data
Population (1991): 9,900,000 
% infants with LBW (1990): 20 
Infant mortality rate (1991): 144/1000 
Under-5 mortality (1991): 228/1000 
Annual number of under-5 deaths (1991): 123,000 
Total fertility rate (1991): 7.6
Years o f CCCD Involvement: 1984-1987 
Limited scope grant agreement: 1988-90 
Atlanta-based CCCD support: 1990-93
National Organization and CDC Resident Staff
National CCCD Program Managers:
Dr. Jean Kalilani, Mr. Geoffrey Lungu,
Dr. Alice Msachi 
National Malaria Coordinators:
Mr. Alan Macheso, Dr. Jack Wirima 
Technical Officer:




A.I.D., EC, ODA, UNICEF, World Bank
N O T A B L E  C C C D  ACTIVITIES  IN MALAWI: M A L A R IA
Malaria Policy and Program Development
Written CCCD malaria policy approved: 1985 
Malaria coordinator named: 1984
Operations Research
Drug Studies (in vivo testing by national or international teams)
1984
Conducted a study among 246 children less than 5 years of age to test the success of 25 m g / 
kg CQ
• Dosing regimen successful in clearing symptoms
• 90% of children responded clinically within 7 days, but 60% continued to have low-grade 
parasitemia on day 7
• Country adopted this regimen as primary therapy for malaria
Studied the efficacy of AQ, SP, and CQ among 152 children less than 5 years of age in 
Lilongwe
• AQ and SP superior to CQ in clearing parasites promptly
• SP superior to AQ in keeping children free of parasites
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1985
Evaluated response of 94 children in Lilongwe to 25 m g/kg of CQ; clinical success or failure 
defined by "illness" index scores
• By day 7, 73% were clinical successes
• By day 14, 46% of those followed remained clinically improved
1985-86
Conducted a study of febrile children given CQ at outpatient health facilities in 2 sites
• Found clinical signs and symptoms associated with parasite density; at both sites, axillary 
temperature >37.3°C was associated with parasite density; at another, history of fever in 
the preceding 48 hours, reduced appetite, and reduced fluid intake were also associated 
with parasite density
1986
A study of 25 children in Lilongwe showed that quinine remained effective in controlling 
parasitemia in a setting of CQ resistance
1987
Studied the efficacy of halofantrine among 49 children less than 5 years of age in towns on 
the west coast of Lake Malawi
• Halofantrine found effective against P. falciparum parasites sensitive and resistant to CQ
• Malaria treated with a single dose of halofantrine (16 m g/kg) showed a high recrudes­
cence rate on day 14 (38%)
• The cure rate was 96% with a 3-dose schedule of 8 m g/kg
1988
Among 121 children less than 5 years of age in Mangochi, mefloquine (MQ) proved to be 
an effective therapy, but therapy was complicated by frequent vomiting
1990
Assessed the clinical, parasitologic, and hematologic responses of 153 young children to CQ 
and SP
• Children treated with SP maintained clinical improvement and had greater increases in 
their hemoglobin concentration than did those treated with CQ
• Concluded that CQ should no longer be considered adequate to treat clinical falciparum 
malaria in very young children in these areas of Africa
Found that cotrimoxazole may treat effectively both febrile illness and acute lower respira­
tory tract infection in young children in malaria-endemic areas
1991
Investigated the efficacy of CQ and SP among pediatric patients less than 3 years of age in 
Mangochi
• A high level of CQ resistance (81% RII and RIII) was seen among children treated with 
CQ
• SP was better than CQ in increasing time to clinical failure and level of hematologic 
recovery
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Other Studies
1986
• Showed that weekly chemoprophylaxis among 83 pregnant women in Lilongwe with 
CQ or AQ reduced density of infection and rates of placental infection, but did not pre­
vent infection
1988
Parasitemia rapidly and spontaneously cleared from peripheral circulation of pregnant
women after delivery
• O f the 43 pregnant women in Mangochi, 95% of the women followed for 48 hours after 
delivery became free of parasites
Conducted a cost-effectiveness study of CQ among 642 pregnant women in sites of year-
round and seasonal transmission
• Chloroquine-resistant Plasmodium falciparum and poor compliance levels limited the 
protective efficacy to 8% for a program of antenatal chemoprophylaxis with a prophylac­
tic dose of CQ (300 mg)
• The cost for preventing one infection was unacceptably high
1987-90
Conducted Mangochi Malaria Research Project
• Documented that women in their first or second pregnancies were at greatest risk of 
malaria-associated LBW
• Mefloquine in prophylactic doses reduced the incidence of placental infection, which is 
associated with LBW
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1990
Documented overlap in clinical case definitions for malaria and pneumonia in children 
brought to a hospital in Lilongwe
• O f the 471 children who met the clinical case definition for pneumonia, 95% also met 
the clinical case definition for malaria
Drug Sensitivity Surveillance System (7-day in vivo testing)
1984
Established a national system at 6 sites (Karonga, Nkhota Kota, Mangochi, Rumphi, Mach- 
inga, Lilongwe)
• Testing showed that 57% of 224 children less than 5 years of age had P. falciparum para­
sites resistant to 25 m g/kg CQ
Knowledge, Attitudes, and Practices (KAP) Surveys
1985
• 49% of 748 children ages 12-23 months had a history of recent fever/malaria
1986
Conducted community practice survey on recent malaria episodes
• 64% of 526 children less than 5 years of age in Salima District had a history of recent 
fever/malaria; 44% of those with recent fever/malaria had parasites
• Nationally 46% of children with fever were taken to a health facility; in the lakeshore 
area, 69% were taken to a health facility
Set up special sentinel surveillance system to monitor home treatment practice
• 15% of all febrile children were treated with CQ and 18% given an antipyretic
1992
Conducted a national community practices survey of 1,531 households
• 88% of febrile children less than 5 years of age received an antimalarial within 48 hours 
of onset of fever
• One-quarter of children less than 5 years of age received the correct dose of an antima­
larial
• 93% of recently pregnant women attended an antenatal clinic at least once during their 
pregnancies
• Total cost of malaria prevention and treatment was 7% of household income
Health Unit Practices Surveys
1986
Job performance survey conducted of 86 health workers who had received a refresher course 
for presumptive treatment 1 year before
• Fewer than one-quarter prescribed correct amount of CQ for age or gave an antipyretic
• Over half (52%) took child's temperature
• 90% prescribed CQ
• 91% of mothers not told what to do for child with fever
Reviewed 8,454 records at one sentinel site for all pediatric admissions from 1980 to 1986
• Showed a decrease in the percentage of children treated with parenteral CQ from 54% in 
1980 to 6% in 1986, and a concurrent increase in quinine from fewer than 1% of chil­
dren in 1980 to 24% in 1986
• The use of oral CQ increased from 45% of all malaria admissions in 1980 to 78% in 1986
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• Percentage of children admitted with malaria who were treated with a blood transfusion 
rose from 20% in 1980 to 44% in 1985
Other Malaria-related Activities
1984
• Established sentinel surveillance system
1985
• Malawians trained by CDC to perform in vivo testing provided training and expert con­
sultation to Swaziland
1986
• Trained 12 staff people to operate the interim sentinel surveillance system for malaria
• In conjunction with Sterling Drugs, Ltd., Malawi, designed a malaria treatment poster 
to be displayed in shops and on packages of CQ sold by merchants
• Developed an interim sentinel system to learn about prior treatment of current illness at 
home or in community; data collected in 1986 and 1987 did not show any major 
improvement in home treatment practices
1987
• Studied feasibility, acceptability, and cost of providing CQ through traditional birth 
attendants (TBAs) at the community level in Malawi: TBAs were acceptable to commu­
nity and capable (correct doses recorded for 18% of 300 children treated by health 
workers and 92% of children treated by TBAs); providing for presumptive treatment 
through primary health care at community level was costly
1988
Conducted a cost-effectiveness analysis of health education messages in conjunction with dif­
ferent antimalarials designed to increase compliance among pregnant women
• Found that the addition of a new nonbitter medication was the most cost-effective 
means of improving compliance; use of CQ supplemented by a new health education 
message ranked second
1989
• Review of 1985-1989 5-year plan documented lack of progress in reduction of cases of 
malaria and reduction of death due to malaria; recommendations for a revision of strat­
egies and implementation were made
• The 1990-1994 5-year Plan for Malaria Control was drafted, modified, and approved; 
and elements to improve malaria control efforts were highlighted: improved awareness 
and compliance in the general population; better diagnosis; nationwide treatment; pre­
vention activities; alternative methods of control; improved knowledge of health care 
workers; strengthened reporting, management, and human resource management; and 
increased government and donor support
1991
• Revised national guidelines for malaria treatment
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NIGERIA
Country Data
Population (1991): 88,500,000 
% infants with LBW (1990): 16 
Infant mortality rate (1991): 86/1000 
Under-5 mortality rate (1991): 188/1000 
Annual number of under-5 deaths (1991): 1,008,000 
Total fertility rate (1991): 6.6
Years o f CCCD Involvement: 1986-1993 
Nationwide: 1986-1989 
Focus Local Government Authorities (9 states,
12 Local government areas [LGA], and 4 federal 
focus agencies): 1990-1993
National Organization and CDC Resident Staff
National CCCD Program Director:
Dr. A.O.O. Sorungbe 
National Malaria Coordinator:
Dr. O.J. Ekanem 
Technical Officers:
Mr. James Herrington, Mr. Warren Jones, Dr. Barbara Maciak, Mr. John Nelson 
Epidemiologists:
Dr. Rick Spiegel, Dr. Jason Weisfeld
Major Donors
A.I.D., IDRC, Japanese Technical Assistance, ODA, Rotary International, UNICEF, WHO
N O T A B L E  C C C D  ACTIVITIES  IN NIGERIA: M A L A R IA
Malaria Policy and Program Development
Written CCCD malaria policy approved: 1989 
Malaria coordinator named: Prior to CCCD
Operations Research
1987
• Nigerian Research Review Committee set up to approve operations research proposals
1991
• At end of 1991, 85 protocols submitted, 36 (12 of which were malaria) approved, and
13 completed
Drug Studies (in vivo testing by national or international teams)
•J Resistance to both CQ (Fig. 2-5) and SP spread from the Southeast and became more 
severe
7 4
N I G E R I A
Birnin K e b b i^ ^  _



















A  1989 
Aboh Mbaise 
1988 A
Figure 2-5. Level o f  Early and Late Parasitologic Failures to Chloroquine Therapy, 
Children Less than 5 Years o f  Age, National Malaria Surveillance Network, 





1 -9% Low 
10-24% Moderate 
> 25% High
Year = Study Date
National Malaria Surveillance Network (14-day in vivo testing)
1987
• Antimalarial drug sensitivity network established involving 4 universities (Calabar, 
Ibadan, Maiduguri, Zaria) and the Federal M OH (FMOH)
Other Studies
1988
Conducted a pilot project to provide background information on the slide positivity rates on
the Jos Plateau and to assess attitudes toward the use of bed nets
• O f the 1,617 children less than 18 years of age examined, the mean slide positivity rate 
was 32% over 2 seasons
• Attitudes toward bed-net use favorable in Amo Katako
• Impregnated bed nets not used adequately in the homes where they were installed for 5 
weeks
Conducted in vivo and in vitro studies of the efficacy of pyrimethamine for suppressive or
causal prophylaxis among pregnant women in Ilorin
• 67% of in vivo tests and 60% of in vitro tests showed pyrimethamine resistance when 
given as suppressive prophylaxis
• A study group given pyrimethamine as causal prophylaxis had no fewer parasitologic fail­
ures than the control group; thus, pyrimethamine was not effective as causal prophylaxis
1991
• Conducted a study of drug quality control for antimalarials and antibiotics; sampled at 
all levels of the drug supply system; drug assays done at Nigerian Government Drug 
Testing Facility; data not yet available
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1992
Began 2-year study of permethrin-impregnated bed nets, curtains, and residual wall spray 
with cyanohyalothrin in Nsukka LGA
• Included an economic analysis of expenditures for medical consultations, medicines, and 
transport, and of time lost from work because of malaria, for each of the 4 groups stud­
ied
Knowledge, Attitudes, and Practices (KAP) Surveys
1991
Conducted a community survey of 1,160 mothers and 1,638 children less than 5 years of 
age in the former Suleja LGA (which in August 1991 was divided into 2 LGAs, Suleja and 
Gurara)
•  About one-quarter of the children had an episode of fever in the 2 weeks prior to the 
survey; each child less than 5 years of age experienced an estimated 8.8 episodes of fever 
in 1991
•  Among febrile children, 90% were treated at home; 65% were given CQ at home
• About 6 in 10 children were taken to a health facility for treatment; 82% of children 
received CQ; 68% of children with fever were given an antimalarial injection
•  Combining data from home and health facility treatment shows that about 35% of chil­
dren given CQ received a correct dose on days 1 and 2, and about 10% on the third day; 
overdosing was most common on day 3
1992
Conducted a community survey of 1,160 mothers and 1,605 children younger than 5 years 
of age in Barkin-Ladi, an LGA in Plateau State
•  Almost one-third of the children less than 5 years of age (31.5%) had an episode of fever 
in the 2 weeks prior to the survey; each child was estimated to experience 6.6 episodes of 
fever per year
•  Among febrile children, 54% were treated with medicine at home; 27% were given CQ 
(the only antimalarial given by mothers in this survey) at home
• O f all febrile children, nearly half (46%) were taken to a health facility; 84% of those 
treated at a health facility were given CQ; about one third (32%) received an antimalar­
ial injection
•  Data from home and facility treatment show that about 35% of children who were given 
CQ received correct doses on days 1 and 2, and about 10% on the third day, when over­
dosing was common; this pattern held true regardless o f where the children received 
treatment
Health Unit Practices Surveys
1988
Assessed quality of health worker delivery of care in 30 health facilities in Niger State
•  Calculation of CQ dosage rarely based on age or weight
•  CQ in some form given to 98% of 56 children seeking treatment for fever, 54% as injec­
tions
•  Correct oral dosage given to 82% of children younger than 12 months of age; correct 
oral dosage given to 8% of children older than 12 months
1989
Previous study repeated in 27 health facilities
• In 101 observations, 98% prescribed antimalarial; 45% received correct dose
76
N I G E R I A
•  62% prescribed injection and syrup, 2% injection only, 7% injection and tablet
•  10% of facilities had no CQ tablets or syrup
• 15% of 101 mothers told to bring child back in 3 days if fever continued
1991
Conducted a survey of all 11 government health facilities in Nsukka, an LGA in Enugu State
•  The majority of children given some form of CQ: about one-quarter were given tablets, 
one-third were given syrup, and one-third were given an injection
• Nearly 1 in 3 mothers were told how to administer malaria medications; few (11%) were 
told the importance of completing the 3-day treatment
Conducted a survey of 13 government primary health care facilities in Barkin-Ladi, an LGA
in Plateau State
• Approximately 96% of 49 children were given some form of CQ; more than one-third 
(37%) were given tablets, 51% syrup, and one-third injections
•  Nearly all mothers (91%) were told how to administer malaria medications, but only 
one-quarter were told the importance of completing the 3-day treatment
Demographic and Health Survey (DHS)
1990
•  Nearly a third of 7,028 children younger than 5 years o f age reported fever during the 2 
weeks prior to the survey
•  About 2 in 10 (21%) of those with fever received antimalarials
•  Children of urban mothers and more well -educated mothers were more likely to be 
taken to a health facility for treatment of their fever
•  30% were taken to a health facility or provider
Other Malaria-related Activities
1988-89
• Sentinel surveillance at University College Hospital in Ibadan documented an increase in 
the percentage of outpatient department consultations diagnosed as malaria
1989-90
•  Operational research study documented substandard low potency CQ syrup in about 
one-third of commercially acquired samples in eastern Nigeria
•  Malaria sentinel surveillance continued at selected health facilities
• Instituted expanded use of microscopy
•  Malaria training module developed to be incorporated into the training program, pre­
tested in Niger State, and approved for use throughout country
1990
• Primary Health Care (PHC) sentinel surveillance system designed
1990-91
• 4th Annual Health Education Management Workshop conducted by African Regional 
Health Education Center (ARHEC), University of North Carolina, and International 
Health Program Office, CDC: Health Education for Malaria Control in the Context of a 
Primary Health Care Approach
• The College of Medical Sciences, University of Calabar, in collaboration with FMOH, 
organized and held the International Workshop on the Current Treatment and Preven­
tion of Malaria at the University of Calabar; 7 countries represented and 11 Nigerian 
universities participated
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•  Computers installed and staff trained in all 4 zonal PHC offices and 9 sentinel hospitals
•  Computerized system established and integrated into the national PHC system
1991
•  LGA Malaria Initiative begun, a multidisciplinary approach to incorporate a variety of 
program components: training, health education, logistics, health information systems, 
and operational research; 4 LGAs (Barkin-Ladi, Suleja, Ife-Central, Nsukka) selected for 
intensification of malaria control activities during 1991-1993; a joint collaboration by 
FMOH, State MOH, LGA Department, and CCCD
• First issue of Nigeria Bulletin of Epidemiology published; 3 issues published in 1991
1992
•  Installed computers in 8 hospitals to monitor inpatient morbidity and mortality
•  3 issues of Nigeria Bulletin of Epidemiology published
1987-1993
•  Held biannual meetings of National Malaria Surveillance Network
•  National Malaria Surveillance Network, composed of 4 universities and the Federal 
MOH, monitored drug sensitivity
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Country Data
Population (1991): 7,300,000 
% infants with LBW ( 1990) : 17 
Infant mortality rate (1991): 112/1000 
Under-5 mortality rate (1990): 189/1000 
Annual number of under-5 deaths (1991) 71,000 
Total fertility rate (1991): 8.5
Years o f CCCD Involvement: 1984-1988
National Organization and CD C Resident Staff
National CCCD Program Director:
Dr. Augustin Ntilivamunda 
National Malaria Coordinator:





N O T A B L E  C C C D  A C T I V I T I E S  IN R W A N D A :  M A L A R I A
Malaria Policy and Program Development
Written CCCD malaria policy approved: 1986 
Malaria coordinating unit created: 1986
Operations Research
Drug Studies (in vivo testing by national or international teams)
1986
Conducted an in vivo and in vitro study of 138 children younger than 6 years o f age in the 
Kigali and Butaré prefectures; study served as baseline surveillance data for following falci­
parum sensitivity to CQ
• In vivo response to CQ both 25 and 50 m g/kg in children showed similar benefits
• Although resistance existed, clinical and parasitologic improvement indicated that CQ 
should still be used
• In vitro testing indicated little resistance to MQ and quinine but high resistance to 
pyrimethamine
Investigated the efficacy of AQ and SP as second-line therapy for CQ-resistant P. falciparum 
in 98 children less than 6 years of age who were still parasitemic 14 days after treatment with 
CQ in Butaré and Kigali
•  Showed both AQ and SP to be effective second-line drugs
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1987
Assessed changes in sensitivity to CQ, SP, and AQ in the region of Butare; to evaluate 
national treatment policy, compared results to the 1986 study
•  No change found
• This study marked the beginning of long-term surveillance in 2 regions 
Drug Sensitivity Surveillance System (7-day in vivo testing)
1987
•  Started long-term surveillance in 2 regions
Other studies
1987
• Conducted entomology study in 3 regions to assess mosquito susceptibility to insecti­
cide
Knowledge, Attitudes, and Practices (KAP) Surveys
1985
Conducted survey in 30 clusters (860 children less than 5 years of age) and in 10 health facil­
ities in 7 prefectures to help develop national control policies and plans
•  More than 4 in 10 (41%) of febrile episodes in children come to the attention of the 
health worker
•  42% treated at health center with injections
•  67% given pills or syrup
•  Very little standardization in doses given of CQ at level o f health centers
•  Antimalarials out-of-stock at health centers
•  Chemoprophylaxis for pregnant women not practiced
1986
Held focus group interviews to learn maternal, family, and community KAP about treatment 
of malaria
•  Mothers were aware of the signs of malaria
•  Mothers were willing to go to clinic if they suspected malaria
•  Mothers' understanding of the means to prevent malaria was poor (about three-fourths 
believed vaccinations prevented malaria)
Health Unit Practices Surveys
1987
National and district supervisors visited health facilities in 4 regions to assess and correct per­
formance problems
•  During follow-up visits, showed improvement in quality of care in health facilities that 




•  At CCCD workshop in Zaire, 4 staff plus a technical officer trained to carry out in vivo 
drug response testing
• Initiated an intensive supervision plan to identify performance problems and monitor 
effectiveness of training to correct identified deficiencies
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1986
•  Increased standardized presumptive treatment of fever in children younger than 5 years 
of age from 43 health centers in 1985 to 86 health centers in 1986
1986-87
•  Sentinel surveillance system established; documented increases in malaria morbidity 
between 1980 and 1987
1987
•  Printed and distributed a graphic malaria treatment poster to guide health workers; 
poster served as prototype for several other African countries (Fig. 2-6)
• CDC malariologist brought in to assess the great increase in malaria morbidity; recom­
mended need to emphasize early diagnosis, rapid treatment, and return to a medical 
facility if treatment did not reduce fever, among other measures
1987-88
• After research for therapy failures, SP was chosen as a second-line drug; research led to 
policy change
1988
• By end of project, all central office staff trained to conduct in vivo testing, as well as to 
take and read thick and thin slides to detect malaria
•  Reported malaria morbidity and mortality nearly doubled between 1987 and 1988
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Figure 2-6. Malaria Treatment Poster
TRAITEMENT DU PALUDISME 
1987
PERSONNE avec FIEVRE
CHLOROQUINE ou AMODIAQUINE 

















10 mg/kg le 1e jour 
10 mg/Kg le 2e jour 
5 mg/Kg le 3e jour
FIEVRE - Malade guéri
G .E .- CHERCHER AUTRES CAUSES DE LA FIEVRE
■+ 0 -1 1  mois 1/4 comprimé
1 -  3 ans 1/2 comprimé
4 -1 1  ans 1 comprime
1 1 -1 6  ans 2 comprimes
-► 16 ans et plus 3 comprimes
1 comp/20 kg en dose unique 
1 comprimé = 525 mg
FIEVRE— Malade guéri
G. E .- CHERCHER AUTRES CAUSES DE LA FIEVRE
QUININE P.O. 20 mg/kg/jr en 3 prises pendant au moins 7 jours





A LA CONSCIENCE QUININE IV SI AMELIORATION QUININE IV
20 mg/kg en trois prises 
pendant au moins 7 jours
— ------- 10 mg/kg par prise dilué à 1 gr/l 
administré pendant 2 - 4  heures 
dose a répeter toutes les 8 heures
DOSE D'ENTRETIEN 20 mg/kg dilué à 1 gr/l 
administré pendant 4 
heures
84
R W A N D A
S e l e c t e d  R e f e r e n c e s
Bugilimfura, L., Ngabonziza, C., Nemeyimana, N., and Buzizi, J.M.V. 1988. Efficacité de la 
chloroquine, de l'amodiaquine et de l'association pyriméthamine-sulfadoxine pour le traite­
ment du paludisme à Gikonko. Revue Médicale Rwandaise. 20:93-7.
Deloron, R, Sexton, J.D., Bugilimfura, L., and Sezibera, C. 1988. Amodiaquine and sulfa- 
doxine-pyrimethamine as treatment for chloroquine-resistant Plasmodium falciparum in 
Rwanda. Am J Trop Med Hyg. 38:244-8.
Deming, M.S., Gayibor, A., Murphy, K., Jones, T.S., and Karsa, T. 1989. Home treatment 
of febrile children with antimalarial drugs in Togo. Bull World Health Organ. 67:695-700.
Glik, D., Parker, K., Muligande, G., and Hategikamana, B. 1986. Integrating qualitative and 
quantitative survey techniques. International Quarterly of Community Health Education. 
7(3):181-200.
Sexton, J.D., Deloron, P., Bugilimfura, L., Ntilivamunda, A., and Neill, M. 1988. Parasito­
logic and clinical efficacy of 25 and 50 m g/kg of chloroquine for treatment of Plasmodium 
falciparum malaria in Rwandan children. Am J Trop Med Hyg. 38:237-43.
85
S W A Z I L A N D
S W A Z I L A N D
Country Data
Population (1991): 771,000 
% infants with LBW (1987): 9.6 
Infant mortality rate (1991): 76/1000 
Under-5 mortality rate (1991): 113/1000 
Annual number of under-5 deaths (1991): 3,300 
Total fertility rate (1988): 5.0
Years o f CCCD Involvement: 1984-1992
National Organization and CD C Resident Staff
National CCCD Program Directors:
Dr. Qhing Dlamini, Sister Gladys Matsebula,
Dr. Eddie McGrath (acting), Dr. John Ngubeni 
National Malaria Unit Manager:
Mr. Simon Kunene 
Technical Officers:




A.I.D., Republic o f South Africa, UNICEF, World Bank
N O T A B L E  C C C D  A C T I V I T I E S  IN S W A Z I L A N D :  M A L A R I A
Malaria Policy and Program Development
Written CCCD malaria policy approved: 1988 
Malaria coordinator named: Prior to CCCD
Operations Research
Drug Studies (7-day in vivo testing by national or international teams)
1985
35 parasitémie children younger than 5 years of age in Big Bend and St. Philip's mission 
(lowveld) treated with CQ in a dose of 10 m g/kg
•  34% had parasites resistant to CQ
1987
29 parasitémie children aged 5-13 years from schools located near St. Philips Clinic treated 
with 25 m g/kg of CQ
• 21% parasite-free at day 7
1988
• 70% level of CQ resistance found
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1989
• Follow-up smears of patients treated as outpatients showed the level o f CQ resistance 
dropped from 24% in 1988-1989 to 15% in the last half of 1989; decline attributed to 
absence of drug pressure on the parasite due to restricted use of CQ
Other studies
1990
Conducted a vector insecticide resistance study
• No evidence of resistance in vector mosquitoes (An. gambiae si.) to insecticides used in 
malaria control program
1991
Analyzed data from active and passive case detection
• Malaria morbidity decreased by 50% from previous year
Knowledge, Attitudes, and Practices (KAP) Surveys
1990
Conducted a study in the lowveld of 719 mothers and 833 children
• Almost 25% of children with fever not brought to health center or treated with CQ at 
home
• O f 431 women under 35, 25% took malaria medicine the last time they were pregnant
• O f the children, 1% were treated with antimalarials before going to the clinic
•  76% seen by health worker or in clinic
•  Rural Health Motivators consulted in 11% of fever cases
• Only 3% of those interviewed believed that traditional healers could cure malaria
1991
In January, conducted baseline survey to address mothers' compliance with the malaria treat­
ment regimen in the lowveld area; in July, after staff formulated and implemented a commu­
nications plan, conducted a second survey with 217 people in 56 localities to determine 
effectiveness o f health education messages
•  73% reported completing the prescribed medication
• Nearly 40% had seen or heard information about correct treatment practices
•  25% returned to the clinic if the fever did not decrease by the third day
• 17% sought treatment on the first day of the onset of fever
•  For 74%, the source of information about malaria was a nurse or health worker; interper­
sonal communication the most effective channel for education
Health Unit Practices Surveys
1988
• All hospitals used malaria treatment policy; 25% used prophylaxis policy
• All other health facilities used both
1989
Visited 15 health facilities
•  Seven facilities had CQ in stock; 7 did not
Vector Control
Vector control through spraying historically an essential part o f malaria control program
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1983-87
• Because of inadequate supplies of DDT, homesteads were inadequately or incompletely 
sprayed
1988
•  Spraying coverage, funded by South Africa, increased; used primarily in the lowveld, 
where malaria a significant problem
1989-90
• Further extended spraying coverage; decreased malaria incidence observed at sentinel 
sites (morbidity decreased by 25% since 1987-1988)
1990-91
• Vector control efforts credited with decreasing the number of malaria cases by 55% since 
1988; only CCCD country with decreased malaria incidence (Fig. 2-7)






•  South Africa greatly reduced its financial support in late 1991; the government of 
Swaziland then assumed responsibility for costs of spraying and case detection
Other Malaria-related Activities
1985
•  Staff members taught in vivo drug response testing
1987
•  Printed and distributed national malaria poster
1988-89
• Sentinel surveillance system established at 28 sites
1989
•  Malaria staff outfitted with protective clothing and equipment for use in handling DDT 
and spraying
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•  Joint evaluation of malaria prevention (vector control) and malaria treatment (case man­
agement) completed
•  Developed plans to strengthen surveillance, improve quality control of laboratory ser­
vices, and carry out vector insecticide sensitivity studies
1990
•  Malaria program personnel trained in entomologie field collection, identification tech­
niques, and development of an insecticide susceptibility monitoring system
• Fifth CCCD Consultative Meeting held in Ezulweni
•  50,000 malaria information flyers printed for malaria sprayers to distribute to home­
steads in the lowveld
•  Malaria became a reportable disease and was included in monthly morbidity report
• Assisted 2 program managers to obtain further malaria training at the University of 
South Carolina, U.S.
1988-91
•  Laboratory and field equipment supplied to facilitate research and prevention activities
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Country Data
Population (1991): 3,700,000 
% infants with LBW (1990): 20 
Infant mortality rate (1991): 88/1000 
Under-5 mortality rate (1988): 144/1000 
Annual number of under-5 deaths (1991): 23,000 
Total fertility rate (1991): 6.6
Years o f CCCD Involvement: 1983-1992
National Organization and CD C Resident Staff
National CCCD Program Directors:
Dr. Tchasseu Karsa, Dr. Yao Kassankogyo 
Malaria Control Coordinator:
Dr. Anani Gayibor 
Technical Officers:
Mr. Brian Fitzgibbon, Mr. Kevin Murphy,




A.I.D., FAC, Gesellschaft fur Technische Zusammenarbeit (German Technical Assistance), 
Peace Corps, UNICEF, WHO
N O T A B L E  C C C D  A C T I V I T I E S  IN TOGO:  M A L A R I A
Malaria Policy and Program Development
Written CCCD malaria policy approved: 1985 
Malaria coordinator named: Prior to CCCD
Operations Research
Drug Studies
Active Studies (in vivo testing by national or international teams)
1984-85
•  National drug sensitivity surveillance established
•  98% success rate with 10 m g/kg CQ among children younger than 5 years of age in the 
Maritime, Plateau, and Central Regions
1987
•  37.9% failure rate with 10 m g/kg CQ among 79 Peace Corps volunteers
1988
•  47% (53/113) failure rate with 10 m g/kg CQ; 17% (22/129) with 25 m g/kg AQ; 32% 
(90/278) with 25 m g/kg CQ (Tone, Kozah, Tchaoudjo, Kioto, Golfe)
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Passive Studies (testing day 0 and day 7; only at local health facilities)
1985-present
•  Passive routine monitoring system of drug sensitivity using 25 m g/kg of CQ in Lome
• As a result of studies, presumptive treatment changed from 10 m g/kg to 25 m g/kg in
1988
•  No failures seen in 1985 and 1986 at the Service National du Paludisme (SNP), but 
among children treated with 25 m g/kg at 12 different centers, failure rates rose to 21% 
(91/432 children) in 1988 and 26% (201/769 children) in 1989
Knowledge, Attitudes, and Practices (KAP) Surveys 
1984
•  Nearly 80% of 507 children who had recently had fever were treated at home with CQ in 
Kioto, Wawa, and Haho prefectures
•  Underdosing at home was more frequent than overdosing
• More than 4 of 5 mothers preferred oral medicine for the treatment of malaria
•  CQ was frequently purchased on the open market
1987-88
• 36% of children were underdosed with 10 m g/kg in 1987; 77% were underdosed with 
25 m g/kg in 1988 (Peace Corps volunteers conducted this survey)
1987,1989
• Fever episodes per child increased from 8.8 per year in 1987 to 11.3 in 1989
• Overall, 96% of children with fever were treated at home
• Antimalarials were frequently obtained from open market (64% in 1984, 44% in 1987, 
36% in 1989)
1990 or 1991 Field Survey
• 33% of treated children received recommended dosage of CQ
Health Unit Practices Surveys
1984
• 68% of febrile children treated with quinine injections at health centers in Kioto, Wawa, 
and Haho prefectures
1986
• Antimalarial drug prescribed to all febrile children seeking treatment at the 81 health 
facilities surveyed; 78% were given antimalarial treatment
•  47% received injections
•  57% of treatment doses were correct
•  Use of injections for treatment of malaria declined from 56% in 1983 to 18% in 1986 in 
selected areas
1988
•  47% of treatments at dispensaries were injections
1989
•  In selected areas, quinine injections were used in 9% to 28% of febrile children
91
T O G O
Demographic and Health Surveys (DHS)
1988
• 43% of 2,768 children less than 5 years o f age reported fever or a history of fever in the 
previous 2 weeks
•  Prevalence of fever was higher in rural (45%) than in urban (39%) areas
•  Nearly 31% of children were treated at a health center
•  56.5% of children were given nivaquine, and 11.2% were given injections
Other Malaria-related Activities
•  Trained 600 peripheral health staff members in malaria treatment of uncomplicated ill­
ness and in criteria for referral
•  Trained approximately 100 national and subdivisional staffili diagnosis and management 
of acutely ill patients in context o f drug sensitivity studies
1989
•  After training and supervision, use of injections declined from 47% in 1988 to 9% to 28% 
in 1989 in selected areas
1988-93
• Began health information system in 1988, expanded in 1989 with the installation of 
EPI-INFO software for national surveillance, further expanded in 1990 to include inpa­
tient morbidity and mortality as well as outpatient morbidity (Figs. 2-8 and 2-9)
• Sentinel surveillance system served as a model for the development of facility-based 
reporting in Liberia, Burundi, Nigeria
Figure 2-8. Principal Causes of Hospitalization, Togo, 1989
Diarrhea 5% 









Pediatric Clinic, C H U
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Figure 2-9. Principal Causes o f Death in Children Less than 5 Years o f Age, 
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Country Data
Population (1991): 38,700,000 
% infants with LBW (1990): 15 
Infant mortality rate (1991): 117/1000 
Under-5 mortality rate (1991): 180/1000 
Annual number of under-5 deaths (1991): 333,000 
Total fertility rate (1991): 6.7
Years o f CCCD Involvement: 1982-1991
National Organization and CDC Resident Staff
National CCCD Program Directors:
Dr. Miaka mia Bilenge,
Dr. Helene Mambu ma-Disu, Prof. Musalampasi,
Dr. Kalisa Ruti, Dr. Musinde Sangwa 
National Malaria Coordinator: Dr. K.M. Paluku 
Technical Officers: Mr. John Paul Brennan,
Mr. Jean Roy, Ms. Karen Wilkins 
Regional Epidemiologist:
Dr. Melinda Moore 
Field Epidemiologists:
Dr. Melinda Moore, Dr. William Taylor, Dr. Andrew Vernon
Major Donors
A.I.D., Christian Churches of Zaire, Belgian Assistance (FOMETRO), OXFAM, Rotary 
International, UNICEF, WHO
N O T A B L E  C C C D  A C T I V I T I E S  IN Z A I R E :  M A L A R I A
Malaria Policy and Program Development
Written CCCD malaria policy approved: 1986 
Malaria coordinator named: 1985
Operations Research
Drug Studies (in vivo testing by national and international teams)
1983
First in vivo and in vitro CQ sensitivity tests conducted among 109 Kinshasa school children 
in Kinshasa and Mbuji-Mayi
•  Found no resistance with 10 m g/kg single dose
1984
•  Found resistance to CQ at both 10 and 25 mg levels with in vivo testing in Kinshasa
1985
Conducted a study of P. falciparum resistance to CQ in 4 sites
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• Showed substantial resistance to CQ at 10 m g/kg and relative parasitologic efficacy of 
25 m g/kg: 8% to 71% resistance with CQ at 10 m g/kg and 26% to 56% resistance with 
CQ at 25 m g/kg
• Results led the MOH to recommend 25 m g/kg CQ as first-line treatment for febrile ill­
ness/malaria in the national malaria control plan
1986
In vivo CQ sensitivity data were used to direct a change in treatment policy from 10 m g/kg
to 25 m g/kg
Conducted in vitro study of response to CQ and pyrimethamine among 33 children less than
12 years of age
•  Found resistance to CQ in 82% of isolates and to pyrimethamine in 52% of isolates
•  Showed resistance to AQ at the same level as CQ; quinine and SP showed the greatest 
sensitivity
•  SP recommended as second-line drug for ambulatory cases and quinine as third-line 
drug for severe malaria
1987
Examined the efficacy of quinine among 34 parasitemic children younger than 13 years of
age
•  Quinine found to be effective treatment
Figure 2-10. In Vivo Failures to CQ, Malaria CFRs, Kinshasa and Kivu, 1983-1989 
Percent Chloroqulne Failures Deaths per 100 Cases
Year
Kinshasa —  Kivu D Case Fatality Rate
Drug Sensitivity Surveillance System
1983
•  Sentinel sensitivity surveillance system developed and conducted every 1-2 years 
thereafter
1986
•  Response to antimalarial drugs in pregnant women added to the monitoring network, as 
well as survey of women's attitudes and practices toward chemoprophylaxis
1988
• Follow-up in vivo CQ sensitivity studies in primiparous women documented moderate 
levels of resistance
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• Documented increased risk of malaria to women in their first or second pregnancies
1985
Conducted a study of malaria infection in pregnant women delivering in rural and urban 
maternity centers
•  Women in first or second pregnancies had higher frequencies o f parasitemia, higher par­
asite densities, and higher rates o f still-born infants and LBW babies than other pregnant 
women
• Chemoprophylaxis would be best targeted to women in first or second pregnancies
•  Studies showed fever a poor predictor of malaria infection; reported fever alone tended 
to underestimate the prevalence of parasitemia
1986
Conducted a study among 164 children seeking treatment at Mama Yemo Hospital's emer­
gency ward or the pediatric outpatient clinic in order to investigate association between 
malaria and human immunodeficiency virus (HIV) infection
•  Found that P. falciparum was not associated with HIV infection
Conducted a pediatric ward survey among 167 children less than 12 years of age at Mama 
Yemo Hospital
•  O f all blood transfusions, 87% were given to malaria patients
• A strong dose-response association existed between transfusions and HIV seropositivity
• Treatment o f malaria with blood transfusions considered an important factor in exposure 
of Kinshasa children to HIV infection
Conducted study of 139 patients hospitalized for malaria at 2 hospitals to investigate causes 
of malaria-associated in-hospital mortality
•  Factors associated with death in univariate analyses included young age, female sex, 
greater clinical severity at admission, longer delay before hospitalization, and greater 
cumulative dose of CQ before hospitalization
•  Factors independently associated with mortality included young age, coma, positive 
blood smear, and, to a lesser extent, greater prehospitalization CQ dose (suggesting but 
not confirming clinical CQ resistance)
•  Results used by the national malaria control program to develop more specific educa­
tional messages for specific target groups
1987
Investigated the chemoprophylaxis delivery system at the Kingansani Maternity Center to 
assess the efficacy of monthly CQ chemoprophylaxis in 3,000 pregnant women
• Failed to show any effect on birth weight in the 2,000 women retained in study
•  Methodologic problems existed with study: 1) nonavailability of lab confirmation, pre­
delivery weights, and estimates o f gestational age and duration of pregnancy at enroll­
ment; and 2) 35% loss to follow-up
1988
Conducted a study at Mama Yemo Hospital in Kinshasa among 1,226 children
•  Determined sensitivity and specificity of various diagnostic criteria for acute malaria
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•  Fever a poor predictor of parasitemia and might contribute to overuse of antimalarial 
drugs and undertreatment of other illnesses
•  If fever were sole criterion for antimalarial therapy, 76% would get antimalarials, with a 
diagnostic accuracy of 40% and a treatment accuracy of 24%
• Parasitemic children were more likely to be anemic than those who were free of parasites
•  Pediatric deaths attributed to malaria increased significantly during the first and second 
calendar years at Mama Yemo Hospital
•  Malaria symptoms showed overlap with symptoms of pneumonia and septicemia
Found that parasitemic pregnant women in Kinshasa became free of peripheral parasitemia 
spontaneously without antimalarials after they gave birth
Knowledge, Attitudes, and Practices (KAP) Surveys
Coverage Surveys (conducted from 1980-1988 in Kinshasa and other urban areas, used 
WHO 30-cluster technique) included KAP questions about how children with fevers were 
treated for malaria at home and whether CQ was administered according to the recom­
mended policies
1983
Conducted survey among 3,092 children less than 5 years o f age and 1,791 mothers about 
home treatment
• 37% of children had a fever during the previous 2 weeks
• 69% of febrile children visited a health facility
•  About one-third of febrile children received CQ, no matter where they were treated
•  34% of women took chemoprophylaxis for at least 2 months during their pregnancies
1986
Conducted KAP survey of pregnant women in Kinshasa on treatment and chemoprophylaxis
•  Women treated fevers with CQ, but recommendations on chemoprophylaxis were not 
followed
• Monthly rather than weekly chemoprophylaxis was preferred 
1985-87
Investigators at University of Kinshasa conducted a special survey on malaria in children in 
Kinshasa
• Residents o f one community in Kinshasa commonly took chemoprophylaxis, a practice 
not in agreement with national policy
1990
Conducted a survey on personal protection practices in Kinshasa
•  91% of those bothered by mosquitoes tried to protect themselves from mosquitoes
•  18% of those used bed nets
1991
Conducted a national survey of mothers
•  Percentage of febrile children who received an antimalarial within 24 hours varied from a 
low of 12% in Nord Kivu to 55% in Bas Zaire
Health Unit Practices Surveys
1987
• 70% of hospitals and outpatient facilities provided treatment
• 39% of hospitals and 49% of outpatient facilities provided malaria prophylaxis
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1988
Conducted supervisory visits to 156 health centers
•  Stocks of CQ were frequently interrupted
• 90% of centers had adopted basic strategy of treating children with fever presumptively 
with CQ
• 58% had abandoned chemoprophylaxis in infants
•  35% provided chemoprophylaxis in pregnant women
1989
Conducted supervisory visits in 5 rural health zones
•  Approximately 90% gave oral antimalarial
•  About 20% of mothers told to return if children not better
1990
Conducted supervisory visits in 68 zones
• 14% of zones had stock interruptions for CQ in month prior to visit
•  91% of fever cases treated with CQ, up from 67% in 1989
• Found stability in numbers of cases compared with previous years, but found inconsis­
tent trends in CFRs
Mortality and Use of Health Services (MUHS) Surveys
1984-85
• Baseline surveys conducted in 2 health zones in rural Zaire-in Kingandu and Pai Kongila 
in Bandundu Region
1988-89
Kingandu resurveyed: little change seen in malaria indicators
•  Proportion of children with fever treated presumptively for malaria with CQ basically 
unchanged: 47% in 1984 and 44% in 1988
•  Proportion seen at health facilities the same: 45% in both 1984 and 1988
•  Under-five mortality rate decreased by nearly 22%, presumably due to control of other 
diseases, most notably measles
Other Malaria-related Activities
1984
• Monthly report of presumptive malaria begun at 121 health centers and 43 major hospi­
tals; hospitals also reported cases and deaths among patients diagnosed with malaria
1985-86
•  CCCD health staff members (central and peripheral) trained to conduct in vivo testing
1986
Investigated malaria mortality among hospitalized children
•  Proportional malaria admission rate increased from 29.5% in 1983 to 56.4% in 1986
• Proportional malaria mortality rate increased from 4.8% in 1982 to 15.3% in 1986
Began providing CQ through cost recovery program; produced locally at Laboratoire Phar­
maceutique de Kinshasa
1989
•  Zairian trained by CDC to conduct in vivo testing provided training and expert consul­
tation to Guinea
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1990
• MOH planned to simplify surveillance system by decreasing morbidity and mortality 
data on forms and focusing on the collection of management program process indicators 
o f revised national HIS; civil disturbances prevented implementation
• Produced a treatment poster to be used by health personnel for correct CQ doses by age 
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Report compiled by Jeanne McDermott.
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Notes
Low birth weight (LBW): Less than 2,500 grams (5.5 pounds).
Under-5 mortality rate: Number of deaths of children less than 5 years of age per 1,000 live 
births. More specifically, the probability of dying between birth and exactly 1 year of age.
Total fertility rate: The number of children that would be born per woman, if she were to 
live to the end of her child-bearing years and bear children at each age in accordance with 
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